<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<?covid-19-tdm?>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id>
<journal-title>Frontiers in Immunology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Immunol.</abbrev-journal-title>
<issn pub-type="epub">1664-3224</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fimmu.2024.1353903</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Immunology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Metabolic predictors of COVID-19 mortality and severity: a survival analysis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Abdallah</surname>
<given-names>Abdallah Musa</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/815320"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Doudin</surname>
<given-names>Asmma</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1332595"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sulaiman</surname>
<given-names>Theeb Osama</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2726327"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jamil</surname>
<given-names>Omar</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2726361"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Arif</surname>
<given-names>Rida</given-names>
</name>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2726317"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sada</surname>
<given-names>Fatima Al</given-names>
</name>
<xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2726352"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yassine</surname>
<given-names>Hadi M.</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/318347"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Elrayess</surname>
<given-names>Mohamed A.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/866786"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Elzouki</surname>
<given-names>Abdel-Naser</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1608540"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Emara</surname>
<given-names>Mohamed M.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1101834"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Thillaiappan</surname>
<given-names>Nagendra Babu</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/882977"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Cyprian</surname>
<given-names>Farhan S.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/736240"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>College of Medicine, Qatar University (QU) Health, Qatar University</institution>, <addr-line>Doha</addr-line>, <country>Qatar</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Biomedical Research Center (BRC), Qatar University</institution>, <addr-line>Doha</addr-line>, <country>Qatar</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Department of Medicine, Hamad General Hospital, Hamad Medical Corporation</institution>, <addr-line>Doha</addr-line>, <country>Qatar</country>
</aff>
<aff id="aff4">
<sup>4</sup>
<institution>Department of Radiology, Hamad General Hospital, Hamad Medical Corporation</institution>, <addr-line>Doha</addr-line>, <country>Qatar</country>
</aff>
<aff id="aff5">
<sup>5</sup>
<institution>Emergency Medicine Department, Hamad General Hospital, Hamad Medical Corporation</institution>, <addr-line>Doha</addr-line>, <country>Qatar</country>
</aff>
<aff id="aff6">
<sup>6</sup>
<institution>Neurosurgery Department, Hamad General Hospital, Hamad Medical Corporation</institution>, <addr-line>Doha</addr-line>, <country>Qatar</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Danuta Dudzik, Medical University of Gda&#x144;sk, Poland</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Rafael Mina Piergiorge, Rio de Janeiro State University, Brazil</p>
<p>Debora Decote-Ricardo, Federal Rural University of Rio de Janeiro, Brazil</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Abdallah Musa Abdallah, <email xlink:href="mailto:Abdallah.musa@qu.edu.qa">Abdallah.musa@qu.edu.qa</email>; Farhan S. Cyprian, <email xlink:href="mailto:fcyprian@qu.edu.qa">fcyprian@qu.edu.qa</email>
</p>
</fn>
<fn fn-type="present-address" id="fn003">
<p>&#x2020;Present addresses: Asmma Doudin, Laboratory of Immunoregulation, Research Department, Sidra Medicine, Doha, Qatar; Nagendra Babu Thillaiappan, Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton, United Kingdom</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>10</day>
<month>05</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="collection">
<year>2024</year>
</pub-date>
<volume>15</volume>
<elocation-id>1353903</elocation-id>
<history>
<date date-type="received">
<day>11</day>
<month>12</month>
<year>2023</year>
</date>
<date date-type="accepted">
<day>15</day>
<month>04</month>
<year>2024</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2024 Abdallah, Doudin, Sulaiman, Jamil, Arif, Sada, Yassine, Elrayess, Elzouki, Emara, Thillaiappan and Cyprian</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Abdallah, Doudin, Sulaiman, Jamil, Arif, Sada, Yassine, Elrayess, Elzouki, Emara, Thillaiappan and Cyprian</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<sec>
<title>Introduction</title>
<p>The global healthcare burden of COVID-19 pandemic has been unprecedented with a high mortality. Metabolomics, a powerful technique, has been increasingly utilized to study the host response to infections and to understand the progression of multi-system disorders such as COVID-19. Analysis of the host metabolites in response to SARS-CoV-2 infection can provide a snapshot of the endogenous metabolic landscape of the host and its role in shaping the interaction with SARS-CoV-2. Disease severity and consequently the clinical outcomes may be associated with a metabolic imbalance related to amino acids, lipids, and energy-generating pathways. Hence, the host metabolome can help predict potential clinical risks and outcomes.</p>
</sec>
<sec>
<title>Methods</title>
<p>In this prospective study, using a targeted metabolomics approach, we studied the metabolic signature in 154 COVID-19 patients (males=138, age range 48-69 yrs) and related it to disease severity and mortality. Blood plasma concentrations of metabolites were quantified through LC-MS using MxP Quant 500 kit, which has a coverage of 630 metabolites from 26 biochemical classes including distinct classes of lipids and small organic molecules. We then employed Kaplan-Meier survival analysis to investigate the correlation between various metabolic markers, disease severity and patient outcomes.</p>
</sec>
<sec>
<title>Results</title>
<p>A comparison of survival outcomes between individuals with high levels of various metabolites (amino acids, tryptophan, kynurenine, serotonin, creatine, SDMA, ADMA, 1-MH and carnitine palmitoyltransferase 1 and 2 enzymes) and those with low levels revealed statistically significant differences in survival outcomes. We further used four key metabolic markers (tryptophan, kynurenine, asymmetric dimethylarginine, and 1-Methylhistidine) to develop a COVID-19 mortality risk model through the application of multiple machine-learning methods.</p>
</sec>
<sec>
<title>Conclusions</title>
<p>Metabolomics analysis revealed distinct metabolic signatures among different severity groups, reflecting discernible alterations in amino acid levels and perturbations in tryptophan metabolism. Notably, critical patients exhibited higher levels of short chain acylcarnitines, concomitant with higher concentrations of SDMA, ADMA, and 1-MH in severe cases and non-survivors. Conversely, levels of 3-methylhistidine were lower in this context.</p>
</sec>
</abstract>
<kwd-group>
<kwd>COVID-19</kwd>
<kwd>metabolites</kwd>
<kwd>biomarkers</kwd>
<kwd>severe</kwd>
<kwd>critical</kwd>
<kwd>mortality</kwd>
</kwd-group>
<contract-sponsor id="cn001">Qatar National Library<named-content content-type="fundref-id">10.13039/100019779</named-content>
</contract-sponsor>
<counts>
<fig-count count="6"/>
<table-count count="2"/>
<equation-count count="0"/>
<ref-count count="87"/>
<page-count count="16"/>
<word-count count="6943"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-in-acceptance</meta-name>
<meta-value>Microbial Immunology</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<label>1</label>
<title>Introduction</title>
<p>The coronavirus disease 2019 (COVID-19) pandemic is an infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The global toll of COVID-19 has been unprecedented, which was first reported to the World Health Organization (WHO) on 31 December 2019, and has since caused a major global burden on healthcare, societies, and economies (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>). So far, more than 770 million confirmed COVID-19 cases and around 7 million deaths have been reported globally (<xref ref-type="bibr" rid="B3">3</xref>). COVID-19 mainly presents as a respiratory illness and the clinical spectrum ranges from asymptomatic or mild influenza-like illness to severe pneumonia with severe respiratory distress, which can lead to multi-organ dysfunction and failure, and death (<xref ref-type="bibr" rid="B4">4</xref>&#x2013;<xref ref-type="bibr" rid="B6">6</xref>). An advanced age and pre-existing medical conditions such as hypertension, diabetes, obesity, and smoking amongst others, have been linked to adverse clinical outcomes in COVID-19 (<xref ref-type="bibr" rid="B7">7</xref>&#x2013;<xref ref-type="bibr" rid="B9">9</xref>). Indeed, patients with such characteristics will be at a higher risk of developing a serious illness with severe or life-threatening consequences (<xref ref-type="bibr" rid="B6">6</xref>). There has been a massive and unified global effort to enhance our understanding of the disease and the interaction between the pathogen and the human host, which has resulted in successful production and implementation of a vaccination strategy to control the spread of this disease (<xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B11">11</xref>). However, perturbation of multiple physiological pathways in humans by SARS-CoV-2 and the resultant complexities in clinical presentations, make it challenging to arrive at an accurate patient risk stratification. Higher incidences of adverse clinical outcomes in COVID-19 patients with comorbidities, such as older age, diabetes, dyslipidemia and obesity suggest that metabolic disturbances might play key roles in COVID-19 severity and outcomes (<xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B13">13</xref>). Therefore, to improve clinical management, there is a need to better understand the impact of COVID-19 on host metabolic profile, which might underlie the differences in clinical presentation.</p>
<p>Metabolomics is a powerful technique, which is gaining much traction as potential diagnostic, monitoring and prognostic tool. It allows quantitative analyses of large datasets of biomolecules (also known as metabolites) from host biological specimen, which can provide a broad picture of the metabolome and insights into complex metabolic pathways. This metabolic profile can act as a snapshot of the patient&#x2019;s metabolome, providing a detailed description of the metabolic state as a result of both genetic contributions and environmental factors (<xref ref-type="bibr" rid="B14">14</xref>). Metabolomics can also allow examination of disease-induced changes to the host metabolic landscape and thereby help identify biomarkers of disease severity, predict patient outcomes and facilitate therapeutic intervention (<xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B15">15</xref>).</p>
<p>Metabolomics has been leveraged in biomarker discovery to identify metabolites correlating with diseases. Multiple studies have reported metabolic dysregulation during COVID-19 progression (<xref ref-type="bibr" rid="B16">16</xref>&#x2013;<xref ref-type="bibr" rid="B24">24</xref>) and their effect on multiple organ systems (<xref ref-type="bibr" rid="B19">19</xref>), which suggest that these metabolites may be used as prognostic markers. For example, increases in the ratios of kynurenine to tryptophan (<xref ref-type="bibr" rid="B25">25</xref>, <xref ref-type="bibr" rid="B26">26</xref>), and arginine to ornithine (<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B27">27</xref>) and a decrease in the ratio glutamine to glutamate (<xref ref-type="bibr" rid="B25">25</xref>, <xref ref-type="bibr" rid="B28">28</xref>, <xref ref-type="bibr" rid="B29">29</xref>) have been reported in COVID-19 patients suggestive of COVID-induced metabolic changes. In addition, triglycerides, were also found to be upregulated in COVID-19 patients and it positively correlates with pro-inflammatory markers such as interleukin-6 (IL-6) and C-reactive protein (CRP) (<xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B23">23</xref>, <xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B30">30</xref>). Altogether, these studies have identified alterations in amino acids, lipids, and other crucial metabolic pathways due to COVID-19, however, more research is necessary to characterize and validate biomarkers that can predict the course of the disease, with the ultimate goal of reducing critical complications. In this study, we report the metabolomic changes associated with COVID-19 infection during the early phase of the pandemic from July 2020 to October 2020 and link them to survival probability of COVID-19 patients in Qatar. We aim to stratify patient risk and disease progress based on the metabolic profile and identify biomarkers that are robust in diagnosis and prognosis of COVID-19.</p>
</sec>
<sec id="s2" sec-type="materials|methods">
<label>2</label>
<title>Materials and methods</title>
<sec id="s2_1">
<label>2.1</label>
<title>Study participants</title>
<p>This prospective cohort study included 154 adult patients diagnosed with COVID-19 at Hamad Medical Corporation from July to December 2020. The participants were mostly males (n=138), with a mean age of 55 (range: 48&#x2013;69) and diverse nationalities. Based on the WHO classification of clinical presentation, patients were divided into five age matched groups: asymptomatic (n=36), mild symptomatic (n=23), mild pneumonia (n=32), severe (n=23), and critical (n=40) (<xref ref-type="bibr" rid="B31">31</xref>). Around 10 ml venous blood samples was collected either at the time of diagnosis or hospital admission from all consenting adults above 18 years of age. The plasma was aliquoted after centrifuging the blood samples at 3000 rpm for 5 min at 4&#xb0;C, and stored in -80&#xb0;C. The available clinical and laboratory data, such as body mass index (BMI), viral load, and blood test results, were obtained from the hospital&#x2019;s electronic healthcare system with patients&#x2019; consent. The study was approved by the institutional review boards of Hamad Medical Corporation (MRC-01-20-145) and Qatar University (QU-IRB 1289-EA/20).</p>
</sec>
<sec id="s2_2">
<label>2.2</label>
<title>Metabolomics</title>
<p>The targeted metabolomics of serum samples collected from all participants within 24 to 48 hours after diagnosis was performed using Biocrates MxP<sup>&#xae;</sup> Quant 500 Kit (Biocrates, Innsbruck, Austria). Tandem mass spectrometry was performed at the Fraunhofer Institute for Toxicology and Experimental Medicine. We analyzed 630 metabolites as part of the MetIDQ&#x2122; MetaboINDICATOR&#x2122; module designed for MxP<sup>&#xae;</sup> Quant 500 kit. Lipid quantification was performed using Flow Injection Analysis Tandem Mass Spectrometry (FIA-MS/MS), and small molecule quantification was done using liquid chromatography-tandem mass spectrometry (LC-MS/MS) with the 5500 QTRAP<sup>&#xae;</sup> instrument triple quadrupole mass spectrometer (AB Sciex, Darmstadt, Germany) as previously described (<xref ref-type="bibr" rid="B32">32</xref>, <xref ref-type="bibr" rid="B33">33</xref>).</p>
</sec>
<sec id="s2_3">
<label>2.3</label>
<title>Statistical analysis</title>
<p>All analyses were performed using R version 3.6.3 and python. Data reprocessing was carried out, including normalization by median, log transformation, and Pareto scaling, before clustering to construct the heat-maps. Principal Component Analysis (PCA) was performed to examine the metabolic profiles of COVID-19 patients, with the goal of identifying factors associated with severity and survival. Wilcoxon rank sum tests were implemented to determine the significance of differences between different severity and survival groups. Statistical differences between groups were considered statistically significant if the p-value was less than 0.05. In addition, Receiver Operating Characteristic (ROC) curve analysis was utilized to evaluate the predictive capability of certain metabolites in determining survival status in our cohort. Correlation between certain metabolites and clinical markers was analyzed using the Spearman correlation method. Using Kaplan Meier survival analysis, significant indicators of patient survival related to different metabolite levels were identified, while the Youden method was employed to determine the optimal cut-points for the variables. Survival time was defined as the time from hospital admission to discharge or death. Volcano plots and heat-maps were generated using the Metaboanalyst R package to compare metabolomic differences between patients across different severity groups.</p>
<p>The dataset utilized in this study for creation and testing of models comprises 154 samples, each representing a unique patient record. The dataset summarized in <xref ref-type="table" rid="T1">
<bold>Table&#xa0;1</bold>
</xref>, provides information on demographics, including diabetes and hypertension status as well as age, gender, and body mass index (BMI) (n=154). In this study, various machine learning (ML) algorithms were employed to analyze data with the aim of predicting living status based on metabolic measurements. From the dataset, we tested specific metabolites as predictors for our models, including Tryptophan, Kynurenine, Asymmetric dimethylarginine, and 1-Methylhistidine. These predictors were chosen based on their potential relevance to the living status outcome, literature review and univariate analysis. The dataset of 154 samples was randomly divided into training and testing sets, with 80% of the data used for training and 20% for testing. To enhance reproducibility, we incorporated a random seed using &#x201c;random.seed()&#x201d; function in our code to ensure that data splitting and model initialization, or random processes, yield consistent results across different runs. The ML models, including Logistic Regression, Random Forest Classifier, Support Vector Machine (SVM), Bernoulli Naive Bayes, Gradient Boosting Classifier (using XGBoost), K-Nearest Neighbors (KNN), Neural Network (Multilayer Perceptron), and MLPClassifier were trained using the training set and then used to make predictions on the testing set. The performance of each model was evaluated based on its accuracy and confusion matrix, including the true positives, false positives, true negatives, and false negatives predicted by the model. The python packages used were pandas and scikit-learn (all the codes are available as <xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Material Datasheet 3</bold>
</xref>).</p>
<table-wrap id="T1" position="float">
<label>Table&#xa0;1</label>
<caption>
<p>Clinical traits of participants stratified by asymptomatic, mild symptomatic, mild pneumonia, severe and critical COVID-19 cases.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="top" colspan="3" align="center"/>
<th valign="top" colspan="5" align="center">Severity</th>
<th valign="top" align="center"/>
</tr>
<tr>
<th valign="top" align="center">Characteristic</th>
<th valign="top" align="center">N</th>
<th valign="top" align="center">Total</th>
<th valign="top" align="center">Asymptomatic N = 36<sup>1</sup>
</th>
<th valign="top" align="center">Mild Symptomatic N = 23<sup>1</sup>
</th>
<th valign="top" align="center">Mild Pneumonia N = 32<sup>1</sup>
</th>
<th valign="top" align="center">Severe N = 23<sup>1</sup>
</th>
<th valign="top" align="center">Critical N = 40<sup>1</sup>
</th>
<th valign="top" align="center">p-value<sup>2</sup>
</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">
<bold>Living status</bold>
</td>
<td valign="top" align="center">154</td>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
<td valign="top" align="center">
<bold>&lt;0.001</bold>
</td>
</tr>
<tr>
<td valign="top" align="left">Non-survivor</td>
<td valign="top" align="center"/>
<td valign="top" align="center">33 (100%)</td>
<td valign="top" align="center">0 (0%)</td>
<td valign="top" align="center">0 (0%)</td>
<td valign="top" align="center">1 (3.0%)</td>
<td valign="top" align="center">5 (15%)</td>
<td valign="top" align="center">27 (82%)</td>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" align="left">Survivor</td>
<td valign="top" align="center"/>
<td valign="top" align="center">121 (100%)</td>
<td valign="top" align="center">36 (30%)</td>
<td valign="top" align="center">23 (19%)</td>
<td valign="top" align="center">31 (26%)</td>
<td valign="top" align="center">18 (15%)</td>
<td valign="top" align="center">13 (11%)</td>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" align="left">
<bold>Gender</bold>
</td>
<td valign="top" align="center">154</td>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
<td valign="top" align="center">
<bold>0.011</bold>
</td>
</tr>
<tr>
<td valign="top" align="left">Female</td>
<td valign="top" align="center"/>
<td valign="top" align="center">16 (100%)</td>
<td valign="top" align="center">1 (6.2%)</td>
<td valign="top" align="center">1 (6.2%)</td>
<td valign="top" align="center">9 (56%)</td>
<td valign="top" align="center">1 (6.2%)</td>
<td valign="top" align="center">4 (25%)</td>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" align="left">Male</td>
<td valign="top" align="center"/>
<td valign="top" align="center">138 (100%)</td>
<td valign="top" align="center">35 (25%)</td>
<td valign="top" align="center">22 (16%)</td>
<td valign="top" align="center">23 (17%)</td>
<td valign="top" align="center">22 (16%)</td>
<td valign="top" align="center">36 (26%)</td>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" align="left">
<bold>Age</bold>
</td>
<td valign="top" align="center">154</td>
<td valign="top" align="center">55<break/>(48-63)</td>
<td valign="top" align="center">52 (46-55)</td>
<td valign="top" align="center">52 (46-56)</td>
<td valign="top" align="center">51 (47-61)</td>
<td valign="top" align="center">60 (54-65)</td>
<td valign="top" align="center">64 (56-73)</td>
<td valign="top" align="center">
<bold>&lt;0.001</bold>
</td>
</tr>
<tr>
<td valign="top" align="left">
<bold>Diabetes mellitus</bold>
</td>
<td valign="top" align="center">154</td>
<td valign="top" align="center">77 (100%)</td>
<td valign="top" align="center">12 (16%)</td>
<td valign="top" align="center">12 (16%)</td>
<td valign="top" align="center">18 (23%)</td>
<td valign="top" align="center">12 (16%)</td>
<td valign="top" align="center">23 (30%)</td>
<td valign="top" align="center">0.2</td>
</tr>
<tr>
<td valign="top" align="left">
<bold>Hypertension</bold>
</td>
<td valign="top" align="center">154</td>
<td valign="top" align="center">79 (100%)</td>
<td valign="top" align="center">14 (18%)</td>
<td valign="top" align="center">7 (8.9%)</td>
<td valign="top" align="center">18 (23%)</td>
<td valign="top" align="center">15 (19%)</td>
<td valign="top" align="center">25 (32%)</td>
<td valign="top" align="center">
<bold>0.035</bold>
</td>
</tr>
<tr>
<td valign="top" align="left">
<bold>White blood cell count (WBC) [x10<sup>3</sup>/uL]</bold>
</td>
<td valign="top" align="center">152</td>
<td valign="top" align="center">7.5 (5.6-11.5)</td>
<td valign="top" align="center">6.3 (5.3-7.3)</td>
<td valign="top" align="center">6.2 (5.0-8.8)</td>
<td valign="top" align="center">6.1 (4.4-8.3)</td>
<td valign="top" align="center">9.0 (7.1-12.4)</td>
<td valign="top" align="center">12.6 (8.7-15.8)</td>
<td valign="top" align="center">
<bold>&lt;0.001</bold>
</td>
</tr>
<tr>
<td valign="top" align="left">
<bold>Red blood cell count (RBC) [x10<sup>6</sup>/uL]</bold>
</td>
<td valign="top" align="center">152</td>
<td valign="top" align="center">4.60 (3.60-5.12)</td>
<td valign="top" align="center">5.10 (4.85-5.40)</td>
<td valign="top" align="center">5.25 (4.93-5.77)</td>
<td valign="top" align="center">4.90 (4.50-5.23)</td>
<td valign="top" align="center">4.00 (3.50-4.50)</td>
<td valign="top" align="center">3.10 (2.80-3.82)</td>
<td valign="top" align="center">
<bold>&lt;0.001</bold>
</td>
</tr>
<tr>
<td valign="top" align="left">
<bold>Hemoglobin (Hgb) [g/dL]</bold>
</td>
<td valign="top" align="center">152</td>
<td valign="top" align="center">12.55 (10.47-14.60)</td>
<td valign="top" align="center">14.60 (13.55-15.35)</td>
<td valign="top" align="center">14.80 (13.65-16.08)</td>
<td valign="top" align="center">13.40 (12.38-14.17)</td>
<td valign="top" align="center">11.90 (10.85-12.50)</td>
<td valign="top" align="center">9.15 (8.10-11.05)</td>
<td valign="top" align="center">
<bold>&lt;0.001</bold>
</td>
</tr>
<tr>
<td valign="top" align="left">
<bold>Hematocrit (Hct) [%]</bold>
</td>
<td valign="top" align="center">152</td>
<td valign="top" align="center">38 (32-43)</td>
<td valign="top" align="center">44 (41-45)</td>
<td valign="top" align="center">44 (41-48)</td>
<td valign="top" align="center">40 (38-43)</td>
<td valign="top" align="center">35 (32-37)</td>
<td valign="top" align="center">28 (25-33)</td>
<td valign="top" align="center">
<bold>&lt;0.001</bold>
</td>
</tr>
<tr>
<td valign="top" align="left">
<bold>Mean corpuscular volume (MCV) [fL]</bold>
</td>
<td valign="top" align="center">152</td>
<td valign="top" align="center">86 (82-90)</td>
<td valign="top" align="center">86 (82-89)</td>
<td valign="top" align="center">83 (80-86)</td>
<td valign="top" align="center">84 (76-88)</td>
<td valign="top" align="center">89 (85-93)</td>
<td valign="top" align="center">89 (87-92)</td>
<td valign="top" align="center">
<bold>&lt;0.001</bold>
</td>
</tr>
<tr>
<td valign="top" align="left">
<bold>Absolute neutrophil count (ANC) [x10<sup>3</sup>/uL]</bold>
</td>
<td valign="top" align="center">152</td>
<td valign="top" align="center">5.3 (3.1-8.9)</td>
<td valign="top" align="center">3.7 (2.5-4.7)</td>
<td valign="top" align="center">3.5 (2.1-4.3)</td>
<td valign="top" align="center">3.7 (2.5-5.8)</td>
<td valign="top" align="center">7.3 (5.7-10.7)</td>
<td valign="top" align="center">10.4 (7.5-13.8)</td>
<td valign="top" align="center">
<bold>&lt;0.001</bold>
</td>
</tr>
<tr>
<td valign="top" align="left">
<bold>Lymphocyte count [x10<sup>3</sup>/uL]</bold>
</td>
<td valign="top" align="center">152</td>
<td valign="top" align="center">1.40 (0.98-2.00)</td>
<td valign="top" align="center">1.70 (1.55-2.45)</td>
<td valign="top" align="center">2.00 (1.60-2.40)</td>
<td valign="top" align="center">1.35 (1.08-1.83)</td>
<td valign="top" align="center">1.10 (0.65-1.50)</td>
<td valign="top" align="center">0.90 (0.50-1.40)</td>
<td valign="top" align="center">
<bold>&lt;0.001</bold>
</td>
</tr>
<tr>
<td valign="top" align="left">
<bold>Mean platelet volume (MPV) [fl]</bold>
</td>
<td valign="top" align="center">147</td>
<td valign="top" align="center">10.50 (9.90-11.50)</td>
<td valign="top" align="center">10.10 (9.55-10.95)</td>
<td valign="top" align="center">10.45 (9.70-11.30)</td>
<td valign="top" align="center">10.40 (10.05-10.95)</td>
<td valign="top" align="center">10.40 (9.60-11.45)</td>
<td valign="top" align="center">11.30 (10.38-12.33)</td>
<td valign="top" align="center">
<bold>&lt;0.001</bold>
</td>
</tr>
<tr>
<td valign="top" align="left">
<bold>Red blood cell distribution width (RDW-CV) [%]</bold>
</td>
<td valign="top" align="center">152</td>
<td valign="top" align="center">13.70 (12.60-16.00)</td>
<td valign="top" align="center">12.30 (11.90-12.95)</td>
<td valign="top" align="center">12.80 (12.25-14.00)</td>
<td valign="top" align="center">13.50 (12.67-14.62)</td>
<td valign="top" align="center">14.30 (13.65-15.55)</td>
<td valign="top" align="center">16.65 (14.60-19.52)</td>
<td valign="top" align="center">
<bold>&lt;0.001</bold>
</td>
</tr>
<tr>
<td valign="top" align="left">
<bold>D-Dimer [mg/L FEU]</bold>
</td>
<td valign="top" align="center">103</td>
<td valign="top" align="center">1.35 (0.54-3.77)</td>
<td valign="top" align="center">0.28 (0.24-0.61)</td>
<td valign="top" align="center">0.53 (0.33-1.08)</td>
<td valign="top" align="center">0.48 (0.36-0.69)</td>
<td valign="top" align="center">1.87 (0.84-3.28)</td>
<td valign="top" align="center">3.35 (1.78-5.29)</td>
<td valign="top" align="center">
<bold>&lt;0.001</bold>
</td>
</tr>
<tr>
<td valign="top" align="left">
<bold>Total Protein [g/L]</bold>
</td>
<td valign="top" align="center">132</td>
<td valign="top" align="center">70 (64-76)</td>
<td valign="top" align="center">77 (72-82)</td>
<td valign="top" align="center">73 (72-75)</td>
<td valign="top" align="center">69 (66-72)</td>
<td valign="top" align="center">70 (64-78)</td>
<td valign="top" align="center">64 (57-72)</td>
<td valign="top" align="center">
<bold>&lt;0.001</bold>
</td>
</tr>
<tr>
<td valign="top" align="left">
<bold>Albumin [g/L]</bold>
</td>
<td valign="top" align="center">144</td>
<td valign="top" align="center">31 (25-38)</td>
<td valign="top" align="center">40 (38-44)</td>
<td valign="top" align="center">39 (36-42)</td>
<td valign="top" align="center">32 (30-35)</td>
<td valign="top" align="center">26 (24-30)</td>
<td valign="top" align="center">23 (20-27)</td>
<td valign="top" align="center">
<bold>&lt;0.001</bold>
</td>
</tr>
<tr>
<td valign="top" align="left">
<bold>Alkaline phosphatase (ALP) [U/L]</bold>
</td>
<td valign="top" align="center">138</td>
<td valign="top" align="center">92 (70-129)</td>
<td valign="top" align="center">82 (70-104)</td>
<td valign="top" align="center">63 (60-74)</td>
<td valign="top" align="center">78 (64-94)</td>
<td valign="top" align="center">108 (85-148)</td>
<td valign="top" align="center">150 (96-287)</td>
<td valign="top" align="center">
<bold>&lt;0.001</bold>
</td>
</tr>
<tr>
<td valign="top" align="left">
<bold>Calcium [mmol/L]</bold>
</td>
<td valign="top" align="center">143</td>
<td valign="top" align="center">2.22 (2.12-2.33)</td>
<td valign="top" align="center">2.32 (2.28-2.38)</td>
<td valign="top" align="center">2.33 (2.23-2.40)</td>
<td valign="top" align="center">2.18 (2.14-2.31)</td>
<td valign="top" align="center">2.14 (2.08-2.28)</td>
<td valign="top" align="center">2.12 (2.05-2.20)</td>
<td valign="top" align="center">
<bold>&lt;0.001</bold>
</td>
</tr>
<tr>
<td valign="top" align="left">
<bold>C-reactive protein (CRP) [mg/L]</bold>
</td>
<td valign="top" align="center">152</td>
<td valign="top" align="center">18 (5-69)</td>
<td valign="top" align="center">4 (2-11)</td>
<td valign="top" align="center">3 (2-9)</td>
<td valign="top" align="center">41 (17-83)</td>
<td valign="top" align="center">40 (10-101)</td>
<td valign="top" align="center">67 (40-111)</td>
<td valign="top" align="center">
<bold>&lt;0.001</bold>
</td>
</tr>
<tr>
<td valign="top" align="left">
<bold>Ferritin [ug/L]</bold>
</td>
<td valign="top" align="center">104</td>
<td valign="top" align="center">688 (318-1,371)</td>
<td valign="top" align="center">218 (144-396)</td>
<td valign="top" align="center">265 (114-365)</td>
<td valign="top" align="center">518 (219-860)</td>
<td valign="top" align="center">670 (438-1,124)</td>
<td valign="top" align="center">1,276 (704-2,656)</td>
<td valign="top" align="center">
<bold>&lt;0.001</bold>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>Parametric traits are described with mean &#xb1; sd, non-parametric using median, whilst categorical variables are given in counts. Significant p-values are in bold text.</p>
</fn>
<fn>
<p>
<sup>1</sup>n (%); Median (25%-75%).</p>
</fn>
<fn>
<p>
<sup>2</sup>Fisher&#x2019;s exact test; Kruskal-Wallis rank sum test; Pearson&#x2019;s Chi-squared test.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
</sec>
<sec id="s3" sec-type="results">
<label>3</label>
<title>Results</title>
<sec id="s3_1">
<label>3.1</label>
<title>Characterization of study patients</title>
<p>The study population consisted of 154 SARS-CoV-2 RT-PCR positive COVID-19 cases that presented with asymptomatic, mild symptomatic, mild pneumonia, severe and critical clinical phenotypes. Baseline demographic and clinical characteristics (clinical data with cutoffs across the five severity groups of COVID-19 patients) are summarized in <xref ref-type="table" rid="T1">
<bold>Table&#xa0;1</bold>
</xref>. Cohorts were matched for age and 121 (121/154, 79%) of enrolled patients survived the infection (<xref ref-type="table" rid="T1">
<bold>Table&#xa0;1</bold>
</xref>). Prevalence of diabetes and hypertension were higher in critical group (<xref ref-type="table" rid="T1">
<bold>Table&#xa0;1</bold>
</xref>). Inflammatory biomarkers, such as IL-6 and CRP, are predictive biomarkers in COVID-19 patients (<xref ref-type="bibr" rid="B34">34</xref>) and were significantly increased in the COVID-19-positive groups. <xref ref-type="table" rid="T1">
<bold>Table&#xa0;1</bold>
</xref> summarizes the clinical and laboratory characteristics of the enrolled cohort. Thromboembolic complications have been reported commonly in severe COVID-19 infections. Levels of D-dimer and CRP were significantly elevated in COVID-19 patients, which correlated with severity of COVID-19 symptoms. Our study revealed a positive correlation between serum ferritin levels and disease severity, poor prognosis and mortality, suggesting that ferritin levels could be an indicator of disease severity and clinical outcome (<xref ref-type="table" rid="T1">
<bold>Table&#xa0;1</bold>
</xref>). Increased levels of ferritin in severe disease might indicate an underlying dysregulation in iron metabolism in response to COVID-19 infection. Therefore, monitoring serum ferritin levels can serve as an important predictive biomarker in COVID-19 management. In addition, the decline in serum albumin levels correlated with disease severity and mortality in our COVID-19 cohort. Moreover, our study also revealed that COVID-19 patients with a severe disease and those that did not survive, had higher serum triglycerides compared to those with less severe disease.</p>
</sec>
<sec id="s3_2">
<label>3.2</label>
<title>Stratification of COVID-19 clinical phenotypes using metabolomics</title>
<p>In the current study, we employed Kaplan-Meier survival analysis to evaluate the correlation between metabolic markers that were previously reported and patient outcomes. A hierarchical cluster analysis of identified metabolites revealed that COVID-19 symptoms severity clearly differed in their metabolic signatures, indicating that the observed metabolic alteration is indeed specific to COVID-19 patients (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figure&#xa0;1</bold>
</xref>). 609 metabolites were analyzed in patients classified as asymptomatic (n=36), mild symptomatic (n=23), mild pneumonia (n=32), severe (n=23) and critical (n=40) based on WHO classification. Distinct metabolites allowed for discrimination of COVID-19 clinical symptoms (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figure&#xa0;1</bold>
</xref>) and this was further highlighted by the scaled principal component analysis (PCA), which revealed metabolic phenotypes of sera from COVID-19 asymptomatic/mild symptomatic groups differing substantially from severe/critical groups (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1A</bold>
</xref>). We examined the relationship between survival and metabolic profile of COVID-19 patients and a PCA plot revealed a clear separation between survivors and non-survivors (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1B</bold>
</xref>). Similarly, a PCA plot of neutrophil counts in COVID-19 patients revealed similar distributions as in patients with asymptomatic/mild (ANC=&lt;7) and severe/critical (ANC&gt;7) groups, indicating that a severe disease positively correlates with a high neutrophil count (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1C</bold>
</xref>). An analogous PCA plot of WBC counts (=&lt;10 for asymptomatic/mild and &gt;10 for severe/critical groups) revealed similar results (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1D</bold>
</xref>). The observed clear separations between the COVID-19 clinical phenotypes for neutrophil and WBC counts indicates a potential association between the metabolic changes in these subgroups and disease severity. Neutrophils rely on both the tricarboxylic acid (TCA) cycle and the pentose phosphate pathway (PPP) to achieve their desired outcomes as effector cells by making reactive oxygen species (ROS) (<xref ref-type="bibr" rid="B35">35</xref>). However, when crucial amino acids like arginine and histidine are depleted, it can severely impair the functionality of neutrophils even with high neutrophil count (<xref ref-type="bibr" rid="B36">36</xref>). On the other hand, the proliferation of lymphocytes is contingent upon the availability of tryptophan (<xref ref-type="bibr" rid="B37">37</xref>). Volcano plots highlighted the most differentially expressed metabolites in COVID-19 plasma samples associated with disease severity distinct metabolites in COVID-19 plasma samples compared to controls (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figure&#xa0;1</bold>
</xref>). A comparison of survival rates between individuals presenting with elevated levels of several metabolites, and those with lower levels, revealed statistically significant differences in survival outcomes. These metabolites included amino acids, tryptophan and kynurenine, their associated metabolites, creatine, symmetric dimethylarginine (SDMA), asymmetric dimethylarginine (ADMA), 1-methylhistidine (1-MH), as well as carnitine palmitoyltransferase 1 and 2 enzymes indicators (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figures&#xa0;2</bold>
</xref>, <xref ref-type="supplementary-material" rid="SM1">
<bold>3</bold>
</xref>).</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>Principal components analysis (PCA) for COVID-19 patients based on putative metabolites. <bold>(A)</bold> PCA plot showing the distribution of 609 metabolites in individuals classified as Asymptomatic (green), Mild Symptomatic (orange), Mild Pneumonia (purple), Severe (pink), and Critical (green) based on their clinical symptoms. <bold>(B)</bold> PCA plot showing the distribution of 609 metabolites in individuals classified as survivors (blue) and non-survivors (pink) of COVID-19. <bold>(C)</bold> PCA plot showing the neutrophil counts in COVID-19 patients with asymptomatic/mild (ANC=&lt;7) and severe/critical (ANC&gt;7) groups. <bold>(D)</bold> PCA plot showing the WBC counts in COVID-19 patients with =&lt;10 for asymptomatic/mild and &gt;10 for severe/critical groups.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-15-1353903-g001.tif"/>
</fig>
</sec>
<sec id="s3_3">
<label>3.3</label>
<title>Association between circulating amino acids profile and COVID-19 severity</title>
<p>The severity spectrum of COVID-19 symptoms has been associated with circulating amino acids concentrations (<xref ref-type="bibr" rid="B38">38</xref>). Hence, we examined the correlation between the amino-acid profile and the severity of the disease in COVID-19 patients. We measured the levels of alanine, phenylalanine, tryptophan, serine, cysteine, glutamine, aspartic acid, glutamic acid, and histidine in different clinical phenotypes (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2</bold>
</xref>). We found that levels of certain amino acids, such as alanine, tryptophan, serine, glutamine, and histidine were significantly reduced in critical and severe cases of COVID-19 and this reduction was associated with disease severity (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2</bold>
</xref>). On the other hand, levels of phenylalanine and cysteine were increased in severe and critical patients compared to asymptomatic group (<xref ref-type="fig" rid="f2">
<bold>Figures&#xa0;2B, E</bold>
</xref>). Interestingly, levels of some amino acids, such as serine (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2D</bold>
</xref>) and aspartic acid (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2G</bold>
</xref>) varied among different severity groups. While aspartic acid levels were lowest in critically-ill patients, its levels were highest in those with mild-pneumonia (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2G</bold>
</xref>). These findings suggest that changes to amino acid profile can be associated with severity of COVID-19 symptoms. Moreover, in severe COVID-19 patients, we found an increase in the ratio of phenylalanine to tryptophan (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2J</bold>
</xref>) (suggestive of decreased protein synthesis), as well as a decrease in the ratio of phenylalanine to tyrosine (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2K</bold>
</xref>) (suggesting the utilization to generate neurotransmitters) in comparison to mild and asymptomatic patients. Consistent with other studies, Fisher&#x2019;s ratio correlated negatively with the disease severity (<xref ref-type="bibr" rid="B39">39</xref>) (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2L</bold>
</xref>). Similarly, analysis of serum amino acid levels revealed significant differences between survivors and non-survivors (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3</bold>
</xref>). The levels of alanine, tryptophan, serine, aspartic acid, glutamic acid, and histidine were found to be significantly decreased in individuals who did not survive in comparison to those who did. On the other hand, the levels of phenylalanine were found to be elevated in non-survivors (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3</bold>
</xref>). This data correlates well with the amino acid levels observed in severe/critical cases (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2</bold>
</xref>).</p>
<fig id="f2" position="float">
<label>Figure&#xa0;2</label>
<caption>
<p>Changes in circulating amino acids associated with COVID-19 clinical severity. Box and whisker plots showing the levels of various amino acids in patients classified by severity of illness. Non-polar amino acids <bold>(A&#x2013;C)</bold>, polar uncharged amino acids <bold>(D&#x2013;F)</bold>, Charged amino acids <bold>(G&#x2013;I)</bold>, ratios of phenylalanine to tryptophan <bold>(J)</bold> and to Tyrosine <bold>(K)</bold> are shown. Fishers ratio is depicted <bold>(L)</bold>. The boxes depict the interquartile range (IQR) and the whiskers extend to the most extreme data points that are not outliers. Outliers are indicated by black circles. The following symbols were used to indicate statistical significance in differences in the levels of amino acids between different severity groups NS, *(0.05); **(0.01); ***(0.001); ****(0.0001).</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-15-1353903-g002.tif"/>
</fig>
<fig id="f3" position="float">
<label>Figure&#xa0;3</label>
<caption>
<p>Comparison of the levels of amino acids between COVID-19 patients who survived and those who did not. Non-polar amino acids <bold>(A-C)</bold> and polar charged amino acids <bold>(D-G)</bold>. Box plots depict the interquartile range (IQR) and the whiskers extend to the most extreme data points that are not outliers. Outliers are indicated by black circles. The following symbols were used to indicate statistical significance in differences of the levels of amino acids between survivors and non-survivors NS, *(0.05); **(0.01); ***(0.001); ****(0.0001).</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-15-1353903-g003.tif"/>
</fig>
</sec>
<sec id="s3_4">
<label>3.4</label>
<title>Alterations in tryptophan and kynurenine metabolism and kynurenine/tryptophan ratio</title>
<p>Tryptophan is an essential amino acid that plays a vital role in protein synthesis, growth, mental health, and immune responses (<xref ref-type="bibr" rid="B40">40</xref>). Tryptophan pathway was among the top pathways that was impacted by SARS-CoV-2 severe infection. Our analysis revealed that tryptophan derivatives serotonin and tryptophan betaine were significantly reduced in the severe/critical group compared to mild and asymptomatic groups (<xref ref-type="fig" rid="f4">
<bold>Figures&#xa0;4A, B</bold>
</xref>) and this reduction was associated with disease severity. Previous study showed that the levels of tryptophan were significantly decreased in COVID-19 patients and were inversely correlated with IL-6 levels (<xref ref-type="bibr" rid="B41">41</xref>). It is well known that the essential amino acid tryptophan catabolism is tightly controlled by the rate-limiting enzyme indoleamine 2,3-dioxygenase (IDO) (<xref ref-type="bibr" rid="B37">37</xref>). IDO contributes to immune-metabolic regulation by depleting tryptophan or producing kynurenine, which both contributing to an increased susceptibility to infection (<xref ref-type="bibr" rid="B42">42</xref>). Our further analysis showed that 3-indolepropionic acid and kynurenine, the two tryptophan derived metabolites, and the ratios of kynurenine to tryptophan and kynurenine to tryptophan betaine were elevated (<xref ref-type="fig" rid="f4">
<bold>Figures&#xa0;4C, D</bold>
</xref>) in patients with severe/critical COVID-19 (<xref ref-type="fig" rid="f4">
<bold>Figures&#xa0;4E, F</bold>
</xref>). Additionally, receiver operating characteristic (ROC) curve analysis in our total cohort revealed an area under the curve (AUC) of 0.929 and 0.904 for kynurenine and kynurenine to tryptophan ratio respectively (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4G</bold>
</xref>). These results have shown good predictive value to discriminate between hospital deaths and survivors (<xref ref-type="fig" rid="f4">
<bold>Figures&#xa0;4C&#x2013;G</bold>
</xref>). A significant negative correlation between kynurenine to tryptophan ratio and either lymphocyte percentage or albumin were observed with a Pearson coefficient of R=0.61 and 0.72 (p &lt; 0.05), respectively (<xref ref-type="fig" rid="f4">
<bold>Figures&#xa0;4H, I</bold>
</xref>). In accordance with the alterations in metabolite levels mentioned above, patient survival probability in high serotonin (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4J</bold>
</xref>), tryptophan (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4L</bold>
</xref>), and tryptophan betaine (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4M</bold>
</xref>) groups was significantly improved compared to patients with low levels (p &lt; 0.0001). Whereas high levels of kynurenine (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4K</bold>
</xref>) and elevated kynurenine:tryptophan (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4N</bold>
</xref>) and kynurenine:tryptophan betaine ratios (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4O</bold>
</xref>) were associated with decreased survival probability. Taken together, high levels of serotonin, tryptophan, and tryptophan betaine were associated with improved survival, while high levels of kynurenine, kynurenine to tryptophan ratio, and kynurenine to tryptophan betaine ratio were associated with decreased survival probability. Therefore, these metabolites warrant further testing as possible prognostic markers for severe/critical COVID-19 cases.</p>
<fig id="f4" position="float">
<label>Figure&#xa0;4</label>
<caption>
<p>Alterations in tryptophan and kynurenine pathway metabolites. Levels of <bold>(A)</bold> Serotonin, <bold>(B)</bold> Tryptophan betaine, <bold>(C)</bold> 3-indolepropionic acid, <bold>(D)</bold> Kynurenine, <bold>(E)</bold> Kynurenine to tryptophan, and <bold>(F)</bold> Kynurenine to tryptophan betaine in critical, severe, mild, and asymptomatic COVID-19 patients, and their association with patient outcomes. <bold>(G)</bold> ROC curve analysis of Kynurenine and Kynurenine to Tryptophan ratio, <bold>(H)</bold> Spearman correlation between kynurenine to tryptophan ratio and lymphocytes percentage, <bold>(I)</bold> Spearman correlation between kynurenine to tryptophan ratio and albumin, <bold>(J)</bold> COVID-19 survival probability in each high/low serotonin, <bold>(K)</bold> Kynurenine, <bold>(L)</bold> Tryptophan, <bold>(M)</bold> Tryptophan betaine, <bold>(N)</bold> Kynurenine to tryptophan ratio, <bold>(O)</bold> and Kynurenine to tryptophan betaine ratio. p &gt; 0.05; *p &#x2264; 0.05; **p &#x2264; 0.01; ***p &#x2264; 0.001; ****p &#x2264; 0.0001.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-15-1353903-g004.tif"/>
</fig>
</sec>
<sec id="s3_5">
<label>3.5</label>
<title>COVID-19 positive patients display alterations in carnitine metabolism</title>
<p>The effects of SARS-CoV-2 infection on intermediary metabolism, including metabolism of acylcarnitines, has not been well studied. Nevertheless, measurement of total carnitine has been used as a precision biomarker to predict mortality risk in diseases such as sepsis, Type-2 diabetes, cancer, and heart failure (<xref ref-type="bibr" rid="B43">43</xref>). To better understand the dysregulation of acylcarnitine metabolism associated with the COVID-19 symptoms severity, we further analyzed our data for short-chain acylcarnitines (SCACs) concentration. Elevated levels of SCACs have been observed in critically ill COVID-19 patients, likely due to increased demand for energy, inflammation, and mitochondrial dysfunction (<xref ref-type="fig" rid="f5">
<bold>Figure&#xa0;5A</bold>
</xref>). Furthermore, elevated levels of carnitine palmitoyltransferase 1 and 2 (CPT1 and CPT2) enzymes, which are involved in fatty acid transport, have also been observed in critical COVID-19 patients as compared to asymptomatic (<xref ref-type="fig" rid="f5">
<bold>Figures&#xa0;5B, C</bold>
</xref>). ROC curve analysis demonstrated a high discriminatory power for carnitines and CPT1 indicator, with an area under the curve of 0.886 and 0.812 respectively, indicating their potential usefulness as predictors of hospital mortality in COVID-19 patients (<xref ref-type="fig" rid="f5">
<bold>Figure&#xa0;5D</bold>
</xref>). In addition, a positive correlation between acetylcarnitine and propionylcarnitine, the amino acid derivatives involved in fatty acid transport, and urea, a waste product of protein metabolism, was observed in COVID-19 patients (<xref ref-type="fig" rid="f5">
<bold>Figures&#xa0;5E, F</bold>
</xref>). Moreover, we utilized Kaplan-Meier survival curves to analyze the relationship between various metabolic markers and patient outcomes. Our analysis showed that patients with elevated levels of carnitine (<xref ref-type="fig" rid="f5">
<bold>Figure&#xa0;5G</bold>
</xref>), acylcarnitines (<xref ref-type="fig" rid="f5">
<bold>Figures&#xa0;5H&#x2013;K</bold>
</xref>), and CPT1 (<xref ref-type="fig" rid="f5">
<bold>Figure&#xa0;5L</bold>
</xref>) markers had a poor survival outcome probability compared to those with normal levels. These findings suggest that these metabolic markers may have a potential prognostic value in COVID-19 patients and may be useful in the management of the disease.</p>
<fig id="f5" position="float">
<label>Figure&#xa0;5</label>
<caption>
<p>Metabolic markers in different COVID-19 severity groups. <bold>(A)</bold> Short chain acylcarnitines (SCACs). <bold>(B, C)</bold> Carnitine palmitoyltransferase 1 and 2 (CPT1 and CPT2) enzymes. <bold>(D)</bold> Receiver operating characteristic (ROC) curve analysis for carnitines and CPT1 indicators. <bold>(E, F)</bold> Correlation of acetylcarnitine and propionylcarnitine with urea. <bold>(G&#x2013;L)</bold> Kaplan-Meier survival curves for carnitine, acylcarnitines, and CPT1. p &gt; 0.05; *p &#x2264; 0.05; **p &#x2264; 0.01; ***p &#x2264; 0.001; ****p &#x2264; 0.0001.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-15-1353903-g005.tif"/>
</fig>
</sec>
<sec id="s3_6">
<label>3.6</label>
<title>Arginine metabolism and methylhistidines levels in non-survivors and severe cases</title>
<p>Recent reports show that arginine, one of the key amino acids involved in many different biological processes, could also play a crucial role in the COVID-19 infection (<xref ref-type="bibr" rid="B44">44</xref>). It is a substrate for nitric oxide (NO) synthase (NOS) (<xref ref-type="bibr" rid="B45">45</xref>) to generate NO, which is a major endothelial relaxation factor (<xref ref-type="bibr" rid="B46">46</xref>). In addition, arginine serves as a precursor for molecules such as SDMA and ADMA (<xref ref-type="bibr" rid="B46">46</xref>, <xref ref-type="bibr" rid="B47">47</xref>). SDMA and ADMA are endogenous modulators of NO synthesis and intracellular arginine availability in the endothelium (<xref ref-type="bibr" rid="B48">48</xref>) and their circulating concentrations are known to be dysregulated in hypoxia (<xref ref-type="bibr" rid="B49">49</xref>). In addition, inhibition of NO synthesis by ADMA and SDMA may affect immune responses and inflammatory reaction, as they also interfere with inducible NO synthase, an enzyme that is upregulated by inflammatory cytokines (<xref ref-type="bibr" rid="B50">50</xref>). Furthermore, serum SDMA and ADMA were found to be significantly elevated in critical and severe COVID-19 patients, than in other groups and were significantly associated with disease severity (<xref ref-type="bibr" rid="B44">44</xref>). Our analyses showed that patients with severe/critical disease had significantly increased levels of SDMA and ADMA (<xref ref-type="fig" rid="f6">
<bold>Figures&#xa0;6A, B</bold>
</xref>) and 1-methylhistidine (1-MH) (<xref ref-type="fig" rid="f6">
<bold>Figure&#xa0;6C</bold>
</xref>), and non-survivors had even higher levels (<xref ref-type="fig" rid="f6">
<bold>Figures&#xa0;6E&#x2013;G</bold>
</xref>). Conversely, 3-methylhistidine levels were lower in patients with severe disease (<xref ref-type="fig" rid="f6">
<bold>Figure&#xa0;6D</bold>
</xref>) and in non-survivors (<xref ref-type="fig" rid="f6">
<bold>Figure&#xa0;6H</bold>
</xref>). We also found that SDMA, ADMA, and 1-MH are good predictors of patient outcomes in COVID-19, as shown by the high discriminatory power with an AUC of 0.817, 0.778, and 0.881 respectively, which indicate their potential as useful biomarkers (<xref ref-type="fig" rid="f6">
<bold>Figure&#xa0;6I</bold>
</xref>). A positive correlation was observed between urea, 1-MH and SDMA levels in COVID-19 patients (<xref ref-type="fig" rid="f6">
<bold>Figures&#xa0;6J, K</bold>
</xref>). Consistent with other studies, survival probabilities were found to be higher when levels of SDMA, ADMA (<xref ref-type="fig" rid="f6">
<bold>Figures&#xa0;6L, M</bold>
</xref>) and 1-methylhistidine (<xref ref-type="fig" rid="f6">
<bold>Figure&#xa0;6N</bold>
</xref>) were reduced, confirming the association of ADMA, SDMA with COVID-19 mortality (<xref ref-type="bibr" rid="B51">51</xref>).</p>
<fig id="f6" position="float">
<label>Figure&#xa0;6</label>
<caption>
<p>Levels of dimethylarginine and methylhistidine metabolites in COVID-19 patients and their association with outcomes. <bold>(A)</bold> Levels of SDMA, <bold>(B)</bold> ADMA, <bold>(C)</bold> 1-MH, and <bold>(D)</bold> 3-MH in patients with severe/critical disease compared to those with mild/moderate disease and asymptomatic cases. <bold>(E)</bold> Levels of SDMA, <bold>(F)</bold> ADMA, <bold>(G)</bold> 1-MH, and <bold>(H)</bold> 3-MH in non-survivors compared to survivors. <bold>(I)</bold> The AUC of SDMA, ADMA, 1-MH as biomarkers for patient outcomes in COVID-19. <bold>(J)</bold> Correlation between urea and 1-MH and <bold>(K)</bold> SDMA concentrations in COVID-19 patients. <bold>(L)</bold> Survival probabilities in relation to SDMA, <bold>(M)</bold> ADMA, and <bold>(N)</bold> 1-MH concentrations. p &gt; 0.05; *p &#x2264; 0.05; **p &#x2264; 0.01; ***p &#x2264; 0.001; ****p &#x2264; 0.0001.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-15-1353903-g006.tif"/>
</fig>
</sec>
<sec id="s3_7">
<label>3.7</label>
<title>Machine learning models to predict mortality risk in Covid-19 patients</title>
<p>Machine learning (ML), a branch of artificial intelligence (AI) that learns from past data to build predictive models (<xref ref-type="bibr" rid="B52">52</xref>), has been applied in different fields in recent times, including medicine. ML is a useful tool to analyze large amounts of data from medical records including images (<xref ref-type="bibr" rid="B53">53</xref>) and to facilitate prediction of disease and clinical decision-making. Recent advances using ML in COVID-19 include estimation of mortality risk and prediction of progression to a severe or critical state and hospital stay duration (<xref ref-type="bibr" rid="B54">54</xref>). Although most studies have predicted the severity of COVID-19 disease and mortality risk using data from radiographic images (<xref ref-type="bibr" rid="B55">55</xref>&#x2013;<xref ref-type="bibr" rid="B58">58</xref>), and laboratory findings (<xref ref-type="bibr" rid="B59">59</xref>), we have attempted to use metabolites data and ML to predict the severity of the disease and mortality risk in patients with COVID-19. We utilized a combination of four predictive biomarkers, namely tryptophan, kynurenine, asymmetric dimethylarginine, and 1-Methylhistidine to propose a mortality risk model. In this context, we used several machine learning methods including Random Forest, Support Vector Machines, Bernoulli Na&#x131;ve Bayes, Gradient Boosting Classifiers, K-Nearest Neighbors, Neural Network, and Logistic Regression. The results showed that Random Forest yielded an accuracy of 96.77%, Support Vector Machine (SVM) 87.1%, Bernoulli Naive Bayes 87.1%, Gradient Boosting Classifier 100%, K-Nearest Neighbors 87.1%, Logistic Regression 93.55%, MLPClassifier 90.32% and Neural Network 90.32%. <xref ref-type="table" rid="T2">
<bold>Table&#xa0;2</bold>
</xref> illustrates that the models were able to accurately predict the risk of mortality using a panel of four metabolomic markers with high sensitivity and specificity.</p>
<table-wrap id="T2" position="float">
<label>Table&#xa0;2</label>
<caption>
<p>Illustrates the results of accuracy of the ML models.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="top" align="left">Model Name</th>
<th valign="top" align="center">Accuracy</th>
<th valign="top" align="center">True Positives</th>
<th valign="top" align="center">False Positives</th>
<th valign="top" align="center">False Negatives</th>
<th valign="top" align="center">True Negatives</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">Random Forest Classifier</td>
<td valign="top" align="left">96.77%</td>
<td valign="top" align="left">26</td>
<td valign="top" align="left">1</td>
<td valign="top" align="left">0</td>
<td valign="top" align="left">4</td>
</tr>
<tr>
<td valign="top" align="left">Support Vector Machine (SVM)</td>
<td valign="top" align="left">87.10%</td>
<td valign="top" align="left">26</td>
<td valign="top" align="left">1</td>
<td valign="top" align="left">3</td>
<td valign="top" align="left">1</td>
</tr>
<tr>
<td valign="top" align="left">Bernoulli Naive Bayes</td>
<td valign="top" align="left">87.10%</td>
<td valign="top" align="left">27</td>
<td valign="top" align="left">0</td>
<td valign="top" align="left">4</td>
<td valign="top" align="left">0</td>
</tr>
<tr>
<td valign="top" align="left">Gradient Boosting Classifier (XGBoost)</td>
<td valign="top" align="left">100%</td>
<td valign="top" align="left">27</td>
<td valign="top" align="left">0</td>
<td valign="top" align="left">0</td>
<td valign="top" align="left">4</td>
</tr>
<tr>
<td valign="top" align="left">K-Nearest Neighbors (KNN)</td>
<td valign="top" align="left">87.10%</td>
<td valign="top" align="left">24</td>
<td valign="top" align="left">3</td>
<td valign="top" align="left">1</td>
<td valign="top" align="left">3</td>
</tr>
<tr>
<td valign="top" align="left">Logistic Regression</td>
<td valign="top" align="left">93.55%</td>
<td valign="top" align="left">26</td>
<td valign="top" align="left">1</td>
<td valign="top" align="left">1</td>
<td valign="top" align="left">3</td>
</tr>
<tr>
<td valign="top" align="left">MLPClassifier (Multilayer Perceptron)</td>
<td valign="top" align="left">90.32%</td>
<td valign="top" align="left">25</td>
<td valign="top" align="left">2</td>
<td valign="top" align="left">1</td>
<td valign="top" align="left">3</td>
</tr>
<tr>
<td valign="top" align="left">Neural Network (Multilayer Perceptron)</td>
<td valign="top" align="left">90.32%</td>
<td valign="top" align="left">25</td>
<td valign="top" align="left">2</td>
<td valign="top" align="left">1</td>
<td valign="top" align="left">3</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
</sec>
<sec id="s4" sec-type="discussion">
<label>4</label>
<title>Discussion</title>
<p>Severe SARS-CoV-2 infection leads to changes in host metabolism promoting viral replication, and alterations in immune responses resulting in long&#x2010;term metabolic complications and sequelae in infected individuals (<xref ref-type="bibr" rid="B60">60</xref>). Emerging research provides compelling evidence that individuals experiencing severe SARS-CoV-2 infections often exhibit multiple metabolic disruptions. In this study, we employed Kaplan-Meier survival analysis to evaluate the correlation between metabolic markers that were previously reported and the patient outcomes. Our findings clearly revealed statistically significant differences in survival outcomes between individuals presenting with altered levels of several metabolites. To our knowledge our study is the first to identify four metabolites using multiple established machine learning models, which can help distinguish between COVID-19 clinical phenotypes and predict mortality risk.</p>
<p>A key finding reported by several COVID-19 studies is that many amino acids and their related metabolites are dysregulated following severe COVID-19 infection, the majority of which are significantly downregulated (<xref ref-type="bibr" rid="B61">61</xref>, <xref ref-type="bibr" rid="B62">62</xref>). Compared to these studies, in our cohort, significant differences in serum amino acid levels between different severity groups and survivors and non-survivors were observed. Amino acids play a key role in immune cell function, tissue regeneration and repair, while an abnormal amino acid metabolism could cause neurological symptoms and multi-organ failure (<xref ref-type="bibr" rid="B63">63</xref>). It is reported that recovered COVID-19 patients have a certain degree of neurological sequelae and patients with severe COVID-19, may develop multi-organ failure during hospitalization (<xref ref-type="bibr" rid="B25">25</xref>, <xref ref-type="bibr" rid="B27">27</xref>). We found that several amino acids and their associated metabolites such as alanine, tryptophan, serine, glutamine, and histidine were significantly reduced, while phenylalanine and tyrosine were upregulated in severe and critical COVID-19 cases. These amino acids are key players in energy metabolism, neurotransmitter production and metabolic homeostasis regulation (<xref ref-type="bibr" rid="B64">64</xref>, <xref ref-type="bibr" rid="B65">65</xref>). Multiple studies have shown that COVID-19 patients had an enriched levels of taurine and hypotaurine metabolic pathways (<xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B66">66</xref>, <xref ref-type="bibr" rid="B67">67</xref>) indicating that an overactive taurine pathway may drive the excessive immune responses. Therefore, amino acid pathways could be promising targets for drug development.</p>
<p>Other amino acids, including tryptophan derivatives, serotonin and tryptophan betaine, 3-indolepropionic acid, and kynurenine remain dysregulated in the severe/critical group. Multiple studies have revealed that the metabolome of COVID-19 patients, including products of the tryptophan/kynurenine pathway, reflects the severity of the disease and thus can be used to predict disease evolution (<xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B68">68</xref>, <xref ref-type="bibr" rid="B69">69</xref>). It has been shown that Interleukin-6 (IL-6) levels were linked to tryptophan metabolism (<xref ref-type="bibr" rid="B26">26</xref>). Furthermore, kynurenine and arginine are known to be essential for the immunosuppressive activity of dendritic cells, which are critical immunomodulators (<xref ref-type="bibr" rid="B70">70</xref>). Consistent with other studies, severe and critical COVID-19 patients showed increased levels of oxidative stress markers, dysregulation of tryptophan metabolism, and renal dysfunction, which correlated with the decreased lymphocyte count (<xref ref-type="bibr" rid="B71">71</xref>, <xref ref-type="bibr" rid="B72">72</xref>). Indeed, several metabolite levels in tryptophan pathway correlated with clinical laboratory markers of inflammation and renal function (<xref ref-type="bibr" rid="B26">26</xref>). Thus, their persistent dysregulation is most likely linked to the underlying molecular mechanism of long-term COVID-19 and requires further investigation and targeted interventions.</p>
<p>It is also worth noting that significantly elevated levels of short chain acylcarnitines and CPT1 were observed in accord with disease progression. Carnitine is a vitamin-like compound that plays an important role in fatty acid metabolism (<xref ref-type="bibr" rid="B73">73</xref>). It is mainly synthesized in the brain, liver and kidney and is primarily stored in the skeletal muscle and heart (<xref ref-type="bibr" rid="B74">74</xref>). Elevated acylcarnitines in COVID-19 patients have been proposed as activators of pro-inflammatory pathways (<xref ref-type="bibr" rid="B75">75</xref>), and their imbalance has been related to ATP depletion (<xref ref-type="bibr" rid="B76">76</xref>). Our results support the idea that COVID-19 patients present an over utilization of lipid beta-oxidation pathway to supply to the high energetic demand (<xref ref-type="bibr" rid="B66">66</xref>). Thus, this could also suggest dysregulation of these metabolites especially, the short chain acylcarnitines, which are fundamental for maintaining optimal energy metabolism. Furthermore, random forest analysis revealed that carnitine, acylcarnitines and CPT1 show excellent performance in survival outcome probability for COVID-19 patients. This suggests that understanding the metabolic changes of carnitine, acylcarnitines and CPT1 during COVID-19 may advance monitoring disease progression and have a potential prognostic value.</p>
<p>An increase in ferritin level was observed and non-survivors had higher serum ferritin level compared to survivors, confirming enrichment of ferroptosis and energy metabolism pathways in patients with COVID-19. The serum of patients with COVID-19 showed an iron imbalance (<xref ref-type="bibr" rid="B77">77</xref>) and significantly elevated ferritin levels were related to disease severity, development of acute respiratory distress syndrome (ARDS) and death in COVID-19 patients (<xref ref-type="bibr" rid="B78">78</xref>&#x2013;<xref ref-type="bibr" rid="B81">81</xref>). Indeed, serum ferritin has recently been identified as one of the predictors of death in COVID-19 patients (<xref ref-type="bibr" rid="B82">82</xref>&#x2013;<xref ref-type="bibr" rid="B84">84</xref>). Furthermore, a recent study has demonstrated that COVID-19 infection causes hemoglobin damage (<xref ref-type="bibr" rid="B85">85</xref>). Consequently, this leads to detachment of porphyrins from iron, release of iron into the circulation resulting in iron overload and subsequent elevation of ferritin levels (<xref ref-type="bibr" rid="B80">80</xref>). Ferritin is a key mediator of immune dysregulation, especially under extreme hyperferritinemia, via direct immune-suppressive and pro-inflammatory effects, which contribute to cytokine storm and multi-organ damage and failure (<xref ref-type="bibr" rid="B86">86</xref>, <xref ref-type="bibr" rid="B87">87</xref>).</p>
<p>ML has been demonstrated to play a significant role in understanding and combating the pandemic, particularly in predicting mortality risk and severity based on laboratory test results. In the present study, we employed multiple well-established ML models to predict the mortality risk model for COVID-19 patients, based on altered metabolites identified through our data and recent literature. This highlights the potential for ML models to provide a clinically valuable tool in predicting mortality risk in COVID-19 patients based on their metabolomic profile and suggests that research efforts should not overlook metabolic signatures of the disease.</p>
<p>A significant contribution in our study is the incorporation of five distinct severity categories, a characteristic less prevalent or non-present in the majority of existing published research. This distinctive approach allows us to explore a broader spectrum of disease progression, enhancing the granularity of our analysis. Additionally, our study uniquely identifies elevated serum SDMA and ADMA concentrations within these severity groups, rather than merely distinguishing between deceased and surviving patients. This study also presents innovative dimensions, including the integration of Kaplan-Meier survival curves and machine learning techniques to evaluate patient outcomes and predict mortality risk. We emphasize the significance of the Kaplan-Meier survival curves in our research, as they provide a dynamic perspective on the correlation between a diverse array of metabolic markers and COVID-19 patient outcomes across time.</p>
<p>The limitation of this study is that the samples used were collected during the early days of the pandemic, which may not reflect the status of vaccinated population cohort that is prevalent. This could potentially impact the generalization of the findings to more recent cases, as the vaccination may impact the metabolic changes observed. We also acknowledge that practical constraints, such as limited sample availability, had led to unequal distributions of samples among different groups. As a limitation, it should be noted that the small number of female participants in our study (n=16) may limit the statistical power to draw definitive conclusions about potential differences between sexes. Future studies with a larger and more balanced representation of both genders can provide more robust insights into gender-specific variations in COVID-19 disease outcomes. Further research is required to better understand the underlying mechanisms of the relationship between these metabolic markers and COVID-19 outcomes.</p>
<p>As a conclusion, the metabolomic fingerprint of COVID-19 related to disease progression is characterized by dysregulation of amino acids and short chain acylcarnitines metabolic pathways, particularly tryptophan and arginine, and fatty acid metabolism. Our data suggest that metabolic dysregulation could induce states of hypoxemia, ferroptosis and other clinical characteristics of COVID-19. The dysregulation of amino acids and metabolites including tryptophan, kynurenine, carnitine, arginine SDMA and ADMA observed in our study was clearly associated with critical outcomes in COVID-19 patients. Therefore, these metabolites could be considered as promising biomarkers to identify patients at risk of poor outcomes in COVID-19. In addition, short chain acylcarnitines and carnitine palmitoyltransferase 1 and 2 enzymes indicators could be considered as promising predictors of hospital mortality and poor survival outcome. Importantly, high serum ferritin level was found to be associated with more severe disease and negative/poor outcome in COVID-19. Thus, serum ferritin level can serve as an important predictive biomarker in COVID-19 management.</p>
<p>Altogether, these findings hold the potential to serve as prognostic markers, aiding in the assessment of disease severity and the prediction of patient outcomes. Notably, the identification of specific metabolites linked to disease progression and mortality risk contribute to more informed clinical decision-making, ultimately enhancing patient care and management strategies as well as COVID-19 prognosis and treatment.</p>
</sec>
<sec id="s5" sec-type="data-availability">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Material</bold>
</xref>. Further inquiries can be directed to the corresponding authors.</p>
</sec>
<sec id="s6" sec-type="ethics-statement">
<title>Ethics statement</title>
<p>The studies involving humans were approved by the studies involving human participants were reviewed and approved by IRBs at Hamad Medical Corporation and Qatar University. The patients/participants provided their written informed consent to participate in this study. The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation in this study was provided by the participants&#x2019; legal guardians/next of kin.</p>
</sec>
<sec id="s7" sec-type="author-contributions">
<title>Author contributions</title>
<p>AA: Conceptualization, Funding acquisition, Project administration, Supervision, Writing &#x2013; original draft, Writing &#x2013; review &amp; editing, Resources. AD: Formal analysis, Methodology, Writing &#x2013; review &amp; editing. TS: Methodology, Writing &#x2013; review &amp; editing. OJ: Methodology, Writing &#x2013; review &amp; editing. RA: Methodology, Writing &#x2013; review &amp; editing. FA: Investigation, Writing &#x2013; review &amp; editing. HY: Funding acquisition, Writing &#x2013; review &amp; editing. MAE: Methodology, Writing &#x2013; review &amp; editing. A-NE: Investigation, Writing &#x2013; review &amp; editing. MME: Investigation, Writing &#x2013; review &amp; editing. NT: Investigation, Visualization, Writing &#x2013; review &amp; editing. FC: Funding acquisition, Conceptualization, Investigation, Methodology, Supervision, Validation, Visualization, Writing &#x2013; original draft, Writing &#x2013; review &amp; editing.</p>
</sec>
</body>
<back>
<sec id="s8" sec-type="funding-information">
<title>Funding</title>
<p>The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the by the QU internal Grant QU-ERG-CMED-2020-3; QU internal grant (QUCG-CMED-21/22-2); and NPRP11S-1212-170092 grant.</p>
</sec>
<ack>
<title>Acknowledgments</title>
<p>We are extremely grateful of the invaluable support of this project by Prof Abdul Latif Al-Khal and Dr. Mohammed Ibn-Masud Danjuma from Hammad Medical Corporation. Their efforts, support, and guidance was critical for timely sample acquisition and their kind inputs and support has improved the quality of our work. We sincerely appreciate their collaboration.</p>
</ack>
<sec id="s9" sec-type="COI-statement">
<title>Conflict of interest </title>
<p>Authors TS, OJ, RA, and A-NE were employed by the Hamad Medical Corporation.</p>
<p>The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s10" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec id="s11" sec-type="supplementary-material">
<title>Supplementary material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fimmu.2024.1353903/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fimmu.2024.1353903/full#supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="DataSheet_1.pdf" id="SM1" mimetype="application/pdf"/>
<supplementary-material xlink:href="DataSheet_2.pdf" id="SM2" mimetype="application/pdf"/>
<supplementary-material xlink:href="DataSheet_3.csv" id="SM3" mimetype="text/csv"/>
<supplementary-material xlink:href="DataSheet_4.csv" id="SM4" mimetype="text/csv"/>
<supplementary-material xlink:href="DataSheet_5.csv" id="SM5" mimetype="text/csv"/>
<supplementary-material xlink:href="DataSheet_6.csv" id="SM6" mimetype="text/csv"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ali</surname> <given-names>I</given-names>
</name>
<name>
<surname>Alharbi</surname> <given-names>OML</given-names>
</name>
</person-group>. <article-title>COVID-19: Disease, management, treatment, and social impact</article-title>. <source>Sci Total Environ</source>. (<year>2020</year>) <volume>728</volume>:<elocation-id>138861</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.scitotenv.2020.138861</pub-id>
</citation>
</ref>
<ref id="B2">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Phelan</surname> <given-names>AL</given-names>
</name>
<name>
<surname>Katz</surname> <given-names>R</given-names>
</name>
<name>
<surname>Gostin</surname> <given-names>LO</given-names>
</name>
</person-group>. <article-title>The novel coronavirus originating in wuhan, China: challenges for global health governance</article-title>. <source>JAMA</source>. (<year>2020</year>) <volume>323</volume>:<page-range>709&#x2013;10</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1001/jama.2020.1097</pub-id>
</citation>
</ref>
<ref id="B3">
<label>3</label>
<citation citation-type="web">
<person-group person-group-type="author">
<collab>WHO</collab>
</person-group>. <article-title>Weekly epidemiological update on COVID-19 - 25 May 2023</article-title> (<year>2023</year>). Available online at: <uri xlink:href="https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19&#x2014;25-may-2023">https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19&#x2014;25-may-2023</uri>.</citation>
</ref>
<ref id="B4">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fu</surname> <given-names>L</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>B</given-names>
</name>
<name>
<surname>Yuan</surname> <given-names>T</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>X</given-names>
</name>
<name>
<surname>Ao</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Fitzpatrick</surname> <given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: A systematic review and meta-analysis</article-title>. <source>J Infect</source>. (<year>2020</year>) <volume>80</volume>:<page-range>656&#x2013;65</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jinf.2020.03.041</pub-id>
</citation>
</ref>
<ref id="B5">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nishiura</surname> <given-names>H</given-names>
</name>
<name>
<surname>Kobayashi</surname> <given-names>T</given-names>
</name>
<name>
<surname>Miyama</surname> <given-names>T</given-names>
</name>
<name>
<surname>Suzuki</surname> <given-names>A</given-names>
</name>
<name>
<surname>Jung</surname> <given-names>SM</given-names>
</name>
<name>
<surname>Hayashi</surname> <given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19)</article-title>. <source>Int J Infect Dis</source>. (<year>2020</year>) <volume>94</volume>:<page-range>154&#x2013;5</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ijid.2020.03.020</pub-id>
</citation>
</ref>
<ref id="B6">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Williamson</surname> <given-names>EJ</given-names>
</name>
<name>
<surname>Walker</surname> <given-names>AJ</given-names>
</name>
<name>
<surname>Bhaskaran</surname> <given-names>K</given-names>
</name>
<name>
<surname>Bacon</surname> <given-names>S</given-names>
</name>
<name>
<surname>Bates</surname> <given-names>C</given-names>
</name>
<name>
<surname>Morton</surname> <given-names>CE</given-names>
</name>
<etal/>
</person-group>. <article-title>Factors associated with COVID-19-related death using OpenSAFELY</article-title>. <source>Nature</source>. (<year>2020</year>) <volume>584</volume>:<page-range>430&#x2013;6</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41586-020-2521-4</pub-id>
</citation>
</ref>
<ref id="B7">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cao</surname> <given-names>H</given-names>
</name>
<name>
<surname>Baranova</surname> <given-names>A</given-names>
</name>
<name>
<surname>Wei</surname> <given-names>X</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>C</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>F</given-names>
</name>
</person-group>. <article-title>Bidirectional causal associations between type 2 diabetes and COVID-19</article-title>. <source>J Med Virol</source>. (<year>2023</year>) <volume>95</volume>:<elocation-id>e28100</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/jmv.28100</pub-id>
</citation>
</ref>
<ref id="B8">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baranova</surname> <given-names>A</given-names>
</name>
<name>
<surname>Cao</surname> <given-names>H</given-names>
</name>
<name>
<surname>Teng</surname> <given-names>S</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>F</given-names>
</name>
</person-group>. <article-title>A phenome-wide investigation of risk factors for severe COVID-19</article-title>. <source>J Med Virol</source>. (<year>2023</year>) <volume>95</volume>:<elocation-id>e28264</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/jmv.28264</pub-id>
</citation>
</ref>
<ref id="B9">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baranova</surname> <given-names>A</given-names>
</name>
<name>
<surname>Cao</surname> <given-names>H</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>F</given-names>
</name>
</person-group>. <article-title>Causal associations and shared genetics between hypertension and COVID-19</article-title>. <source>J Med Virol</source>. (<year>2023</year>) <volume>95</volume>:<elocation-id>e28698</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/jmv.28698</pub-id>
</citation>
</ref>
<ref id="B10">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Polack</surname> <given-names>FP</given-names>
</name>
<name>
<surname>Thomas</surname> <given-names>SJ</given-names>
</name>
<name>
<surname>Kitchin</surname> <given-names>N</given-names>
</name>
<name>
<surname>Absalon</surname> <given-names>J</given-names>
</name>
<name>
<surname>Gurtman</surname> <given-names>A</given-names>
</name>
<name>
<surname>Lockhart</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine</article-title>. <source>N Engl J Med</source>. (<year>2020</year>) <volume>383</volume>:<page-range>2603&#x2013;15</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1056/NEJMoa2034577</pub-id>
</citation>
</ref>
<ref id="B11">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Voysey</surname> <given-names>M</given-names>
</name>
<name>
<surname>Clemens</surname> <given-names>SAC</given-names>
</name>
<name>
<surname>Madhi</surname> <given-names>SA</given-names>
</name>
<name>
<surname>Weckx</surname> <given-names>LY</given-names>
</name>
<name>
<surname>Folegatti</surname> <given-names>PM</given-names>
</name>
<name>
<surname>Aley</surname> <given-names>PK</given-names>
</name>
<etal/>
</person-group>. <article-title>Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK</article-title>. <source>Lancet</source>. (<year>2021</year>) <volume>397</volume>:<fpage>99</fpage>&#x2013;<lpage>111</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/S0140-6736(20)32661-1</pub-id>
</citation>
</ref>
<ref id="B12">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blasco</surname> <given-names>H</given-names>
</name>
<name>
<surname>Bessy</surname> <given-names>C</given-names>
</name>
<name>
<surname>Plantier</surname> <given-names>L</given-names>
</name>
<name>
<surname>Lefevre</surname> <given-names>A</given-names>
</name>
<name>
<surname>Piver</surname> <given-names>E</given-names>
</name>
<name>
<surname>Bernard</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>The specific metabolome profiling of patients infected by SARS-COV-2 supports the key role of tryptophan-nicotinamide pathway and cytosine metabolism</article-title>. <source>Sci Rep</source>. (<year>2020</year>) <volume>10</volume>:<fpage>16824</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41598-020-73966-5</pub-id>
</citation>
</ref>
<ref id="B13">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Denson</surname> <given-names>JL</given-names>
</name>
<name>
<surname>Gillet</surname> <given-names>AS</given-names>
</name>
<name>
<surname>Zu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Brown</surname> <given-names>M</given-names>
</name>
<name>
<surname>Pham</surname> <given-names>T</given-names>
</name>
<name>
<surname>Yoshida</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Metabolic syndrome and acute respiratory distress syndrome in hospitalized patients with COVID-19</article-title>. <source>JAMA Netw Open</source>. (<year>2021</year>) <volume>4</volume>:<elocation-id>e2140568</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1001/jamanetworkopen.2021.40568</pub-id>
</citation>
</ref>
<ref id="B14">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Holmes</surname> <given-names>E</given-names>
</name>
<name>
<surname>Wilson</surname> <given-names>ID</given-names>
</name>
<name>
<surname>Nicholson</surname> <given-names>JK</given-names>
</name>
</person-group>. <article-title>Metabolic phenotyping in health and disease</article-title>. <source>Cell</source>. (<year>2008</year>) <volume>134</volume>:<page-range>714&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.cell.2008.08.026</pub-id>
</citation>
</ref>
<ref id="B15">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Skene</surname> <given-names>DJ</given-names>
</name>
<name>
<surname>Middleton</surname> <given-names>B</given-names>
</name>
<name>
<surname>Fraser</surname> <given-names>CK</given-names>
</name>
<name>
<surname>Pennings</surname> <given-names>JL</given-names>
</name>
<name>
<surname>Kuchel</surname> <given-names>TR</given-names>
</name>
<name>
<surname>Rudiger</surname> <given-names>SR</given-names>
</name>
<etal/>
</person-group>. <article-title>Metabolic profiling of presymptomatic Huntington&#x2019;s disease sheep reveals novel biomarkers</article-title>. <source>Sci Rep</source>. (<year>2017</year>) <volume>7</volume>:<elocation-id>43030</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/srep43030</pub-id>
</citation>
</ref>
<ref id="B16">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Caterino</surname> <given-names>M</given-names>
</name>
<name>
<surname>Gelzo</surname> <given-names>M</given-names>
</name>
<name>
<surname>Sol</surname> <given-names>S</given-names>
</name>
<name>
<surname>Fedele</surname> <given-names>R</given-names>
</name>
<name>
<surname>Annunziata</surname> <given-names>A</given-names>
</name>
<name>
<surname>Calabrese</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Dysregulation of lipid metabolism and pathological inflammation in patients with COVID-19</article-title>. <source>Sci Rep</source>. (<year>2021</year>) <volume>11</volume>:<fpage>2941</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41598-021-82426-7</pub-id>
</citation>
</ref>
<ref id="B17">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Collier</surname> <given-names>ME</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>S</given-names>
</name>
<name>
<surname>Scrutton</surname> <given-names>NS</given-names>
</name>
<name>
<surname>Giorgini</surname> <given-names>F</given-names>
</name>
</person-group>. <article-title>Inflammation control and improvement of cognitive function in COVID-19 infections: is there a role for kynurenine 3-monooxygenase inhibition</article-title>? <source>Drug Discovery Today</source>. (<year>2021</year>) <volume>26</volume>:<page-range>1473&#x2013;81</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.drudis.2021.02.009</pub-id>
</citation>
</ref>
<ref id="B18">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Danlos</surname> <given-names>FX</given-names>
</name>
<name>
<surname>Grajeda-Iglesias</surname> <given-names>C</given-names>
</name>
<name>
<surname>Durand</surname> <given-names>S</given-names>
</name>
<name>
<surname>Sauvat</surname> <given-names>A</given-names>
</name>
<name>
<surname>Roumier</surname> <given-names>M</given-names>
</name>
<name>
<surname>Cantin</surname> <given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers</article-title>. <source>Cell Death Dis</source>. (<year>2021</year>) <volume>12</volume>:<fpage>258</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41419-021-03540-y</pub-id>
</citation>
</ref>
<ref id="B19">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lawler</surname> <given-names>NG</given-names>
</name>
<name>
<surname>Gray</surname> <given-names>N</given-names>
</name>
<name>
<surname>Kimhofer</surname> <given-names>T</given-names>
</name>
<name>
<surname>Boughton</surname> <given-names>B</given-names>
</name>
<name>
<surname>Gay</surname> <given-names>M</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Systemic perturbations in amine and kynurenine metabolism associated with acute SARS-coV-2 infection and inflammatory cytokine responses</article-title>. <source>J Proteome Res</source>. (<year>2021</year>) <volume>20</volume>:<page-range>2796&#x2013;811</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1021/acs.jproteome.1c00052</pub-id>
</citation>
</ref>
<ref id="B20">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lopez-Hernandez</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Monarrez-Espino</surname> <given-names>J</given-names>
</name>
<name>
<surname>Oostdam</surname> <given-names>AH</given-names>
</name>
<name>
<surname>Delgado</surname> <given-names>JEC</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Zheng</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Targeted metabolomics identifies high performing diagnostic and prognostic biomarkers for COVID-19</article-title>. <source>Sci Rep</source>. (<year>2021</year>) <volume>11</volume>:<fpage>14732</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41598-021-94171-y</pub-id>
</citation>
</ref>
<ref id="B21">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Overmyer</surname> <given-names>KA</given-names>
</name>
<name>
<surname>Shishkova</surname> <given-names>E</given-names>
</name>
<name>
<surname>Miller</surname> <given-names>IJ</given-names>
</name>
<name>
<surname>Balnis</surname> <given-names>J</given-names>
</name>
<name>
<surname>Bernstein</surname> <given-names>MN</given-names>
</name>
<name>
<surname>Peters-Clarke</surname> <given-names>TM</given-names>
</name>
<etal/>
</person-group>. <article-title>Large-scale multi-omic analysis of COVID-19 severity</article-title>. <source>Cell Syst</source>. (<year>2021</year>) <volume>12</volume>:<fpage>23</fpage>&#x2013;<lpage>40 e27</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.cels.2020.10.003</pub-id>
</citation>
</ref>
<ref id="B22">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pang</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>G</given-names>
</name>
<name>
<surname>Chong</surname> <given-names>J</given-names>
</name>
<name>
<surname>Xia</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>Comprehensive meta-analysis of COVID-19 global metabolomics datasets</article-title>. <source>Metabolites</source>. (<year>2021</year>) <volume>11</volume>(<issue>1</issue>):<fpage>44</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/metabo11010044</pub-id>
</citation>
</ref>
<ref id="B23">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schroeder</surname> <given-names>M</given-names>
</name>
<name>
<surname>Schaumburg</surname> <given-names>B</given-names>
</name>
<name>
<surname>Mueller</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Parplys</surname> <given-names>A</given-names>
</name>
<name>
<surname>Jarczak</surname> <given-names>D</given-names>
</name>
<name>
<surname>Roedl</surname> <given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>High estradiol and low testosterone levels are associated with critical illness in male but not in female COVID-19 patients: a retrospective cohort study</article-title>. <source>Emerg Microbes Infect</source>. (<year>2021</year>) <volume>10</volume>:<page-range>1807&#x2013;18</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1080/22221751.2021.1969869</pub-id>
</citation>
</ref>
<ref id="B24">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xiao</surname> <given-names>N</given-names>
</name>
<name>
<surname>Nie</surname> <given-names>M</given-names>
</name>
<name>
<surname>Pang</surname> <given-names>H</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>B</given-names>
</name>
<name>
<surname>Hu</surname> <given-names>J</given-names>
</name>
<name>
<surname>Meng</surname> <given-names>X</given-names>
</name>
<etal/>
</person-group>. <article-title>Integrated cytokine and metabolite analysis reveals immunometabolic reprogramming in COVID-19 patients with therapeutic implications</article-title>. <source>Nat Commun</source>. (<year>2021</year>) <volume>12</volume>:<fpage>1618</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41467-021-21907-9</pub-id>
</citation>
</ref>
<ref id="B25">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kimhofer</surname> <given-names>T</given-names>
</name>
<name>
<surname>Lodge</surname> <given-names>S</given-names>
</name>
<name>
<surname>Whiley</surname> <given-names>L</given-names>
</name>
<name>
<surname>Gray</surname> <given-names>N</given-names>
</name>
<name>
<surname>Loo</surname> <given-names>RL</given-names>
</name>
<name>
<surname>Lawler</surname> <given-names>NG</given-names>
</name>
<etal/>
</person-group>. <article-title>Integrative modeling of quantitative plasma lipoprotein, metabolic, and amino acid data reveals a multiorgan pathological signature of SARS-coV-2 infection</article-title>. <source>J Proteome Res</source>. (<year>2020</year>) <volume>19</volume>:<page-range>4442&#x2013;54</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1021/acs.jproteome.0c00519</pub-id>
</citation>
</ref>
<ref id="B26">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thomas</surname> <given-names>T</given-names>
</name>
<name>
<surname>Stefanoni</surname> <given-names>D</given-names>
</name>
<name>
<surname>Reisz</surname> <given-names>JA</given-names>
</name>
<name>
<surname>Nemkov</surname> <given-names>T</given-names>
</name>
<name>
<surname>Bertolone</surname> <given-names>L</given-names>
</name>
<name>
<surname>Francis</surname> <given-names>RO</given-names>
</name>
<etal/>
</person-group>. <article-title>COVID-19 infection alters kynurenine and fatty acid metabolism, correlating with IL-6 levels and renal status</article-title>. <source>JCI Insight</source>. (<year>2020</year>) <volume>5</volume>(<issue>14</issue>):<elocation-id>e140327</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1172/jci.insight.140327</pub-id>
</citation>
</ref>
<ref id="B27">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rees</surname> <given-names>CA</given-names>
</name>
<name>
<surname>Rostad</surname> <given-names>CA</given-names>
</name>
<name>
<surname>Mantus</surname> <given-names>G</given-names>
</name>
<name>
<surname>Anderson</surname> <given-names>EJ</given-names>
</name>
<name>
<surname>Chahroudi</surname> <given-names>A</given-names>
</name>
<name>
<surname>Jaggi</surname> <given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>Altered amino acid profile in patients with SARS-CoV-2 infection</article-title>. <source>Proc Natl Acad Sci U.S.A</source>. (<year>2021</year>) <volume>118</volume>(<issue>25</issue>):<elocation-id>e2101708118</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1073/pnas.2101708118</pub-id>
</citation>
</ref>
<ref id="B28">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bharadwaj</surname> <given-names>S</given-names>
</name>
<name>
<surname>Singh</surname> <given-names>M</given-names>
</name>
<name>
<surname>Kirtipal</surname> <given-names>N</given-names>
</name>
<name>
<surname>Kang</surname> <given-names>SG</given-names>
</name>
</person-group>. <article-title>SARS-CoV-2 and glutamine: SARS-CoV-2 triggered pathogenesis via metabolic reprograming of glutamine in host cells</article-title>. <source>Front Mol Biosci</source>. (<year>2020</year>) <volume>7</volume>:<elocation-id>627842</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fmolb.2020.627842</pub-id>
</citation>
</ref>
<ref id="B29">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matsuyama</surname> <given-names>T</given-names>
</name>
<name>
<surname>Yoshinaga</surname> <given-names>SK</given-names>
</name>
<name>
<surname>Shibue</surname> <given-names>K</given-names>
</name>
<name>
<surname>Mak</surname> <given-names>TW</given-names>
</name>
</person-group>. <article-title>Comorbidity-associated glutamine deficiency is a predisposition to severe COVID-19</article-title>. <source>Cell Death Differ</source>. (<year>2021</year>) <volume>28</volume>:<page-range>3199&#x2013;213</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41418-021-00892-y</pub-id>
</citation>
</ref>
<ref id="B30">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname> <given-names>D</given-names>
</name>
<name>
<surname>Shu</surname> <given-names>T</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Song</surname> <given-names>JX</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>M</given-names>
</name>
<name>
<surname>Yao</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Plasma metabolomic and lipidomic alterations associated with COVID-19</article-title>. <source>Natl Sci Rev</source>. (<year>2020</year>) <volume>7</volume>:<page-range>1157&#x2013;68</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/nsr/nwaa086</pub-id>
</citation>
</ref>
<ref id="B31">
<label>31</label>
<citation citation-type="web">
<person-group person-group-type="author">
<collab>WHO</collab>
</person-group>. <article-title>COVID-19: symptoms</article-title> (<year>2023</year>). Available online at: <uri xlink:href="https://www.who.int/westernpacific/emergencies/covid-19/information/asymptomatic-covid-19#:~:text=Symptoms%20of%20COVID%2D19%20can,should%20seek%20immediate%20medical%20attention">https://www.who.int/westernpacific/emergencies/covid-19/information/asymptomatic-covid-19#:~:text=Symptoms%20of%20COVID%2D19%20can,should%20seek%20immediate%20medical%20attention</uri>.</citation>
</ref>
<ref id="B32">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elrayess</surname> <given-names>MA</given-names>
</name>
<name>
<surname>Cyprian</surname> <given-names>FS</given-names>
</name>
<name>
<surname>Abdallah</surname> <given-names>AM</given-names>
</name>
<name>
<surname>Emara</surname> <given-names>MM</given-names>
</name>
<name>
<surname>Diboun</surname> <given-names>I</given-names>
</name>
<name>
<surname>Anwardeen</surname> <given-names>N</given-names>
</name>
<etal/>
</person-group>. <article-title>Metabolic signatures of type 2 diabetes mellitus and hypertension in COVID-19 patients with different disease severity</article-title>. <source>Front Med (Lausanne)</source>. (<year>2021</year>) <volume>8</volume>:<elocation-id>788687</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fmed.2021.788687</pub-id>
</citation>
</ref>
<ref id="B33">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Diboun</surname> <given-names>I</given-names>
</name>
<name>
<surname>Cyprian</surname> <given-names>FS</given-names>
</name>
<name>
<surname>Anwardeen</surname> <given-names>NR</given-names>
</name>
<name>
<surname>Yassine</surname> <given-names>HM</given-names>
</name>
<name>
<surname>Elrayess</surname> <given-names>MA</given-names>
</name>
<name>
<surname>Rahmoon</surname> <given-names>SM</given-names>
</name>
<etal/>
</person-group>. <article-title>Identification of prognostic metabolomic biomarkers at the interface of mortality and morbidity in pre-existing TB cases infected with SARS-coV-2</article-title>. <source>Front Cell Infect Microbiol</source>. (<year>2022</year>) <volume>12</volume>:<elocation-id>929689</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fcimb.2022.929689</pub-id>
</citation>
</ref>
<ref id="B34">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Herold</surname> <given-names>T</given-names>
</name>
<name>
<surname>Jurinovic</surname> <given-names>V</given-names>
</name>
<name>
<surname>Arnreich</surname> <given-names>C</given-names>
</name>
<name>
<surname>Lipworth</surname> <given-names>BJ</given-names>
</name>
<name>
<surname>Hellmuth</surname> <given-names>JC</given-names>
</name>
<name>
<surname>von Bergwelt-Baildon</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19</article-title>. <source>J Allergy Clin Immunol</source>. (<year>2020</year>) <volume>146</volume>:<fpage>128</fpage>&#x2013;<lpage>136 e124</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jaci.2020.05.008</pub-id>
</citation>
</ref>
<ref id="B35">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morrison</surname> <given-names>T</given-names>
</name>
<name>
<surname>Watts</surname> <given-names>ER</given-names>
</name>
<name>
<surname>Sadiku</surname> <given-names>P</given-names>
</name>
<name>
<surname>Walmsley</surname> <given-names>SR</given-names>
</name>
</person-group>. <article-title>The emerging role for metabolism in fueling neutrophilic inflammation</article-title>. <source>Immunol Rev</source>. (<year>2023</year>) <volume>314</volume>:<page-range>427&#x2013;41</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/imr.13157</pub-id>
</citation>
</ref>
<ref id="B36">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Hook</surname> <given-names>JS</given-names>
</name>
<name>
<surname>Ding</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Xiao</surname> <given-names>X</given-names>
</name>
<name>
<surname>Chung</surname> <given-names>SS</given-names>
</name>
<name>
<surname>Mettlen</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Neutrophil metabolomics in severe COVID-19 reveal GAPDH as a suppressor of neutrophil extracellular trap formation</article-title>. <source>Nat Commun</source>. (<year>2023</year>) <volume>14</volume>:<fpage>2610</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41467-023-37567-w</pub-id>
</citation>
</ref>
<ref id="B37">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Munn</surname> <given-names>DH</given-names>
</name>
<name>
<surname>Shafizadeh</surname> <given-names>E</given-names>
</name>
<name>
<surname>Attwood</surname> <given-names>JT</given-names>
</name>
<name>
<surname>Bondarev</surname> <given-names>I</given-names>
</name>
<name>
<surname>Pashine</surname> <given-names>A</given-names>
</name>
<name>
<surname>Mellor</surname> <given-names>AL</given-names>
</name>
</person-group>. <article-title>Inhibition of T cell proliferation by macrophage tryptophan catabolism</article-title>. <source>J Exp Med</source>. (<year>1999</year>) <volume>189</volume>:<page-range>1363&#x2013;72</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1084/jem.189.9.1363</pub-id>
</citation>
</ref>
<ref id="B38">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maltais-Payette</surname> <given-names>I</given-names>
</name>
<name>
<surname>Lajeunesse-Trempe</surname> <given-names>F</given-names>
</name>
<name>
<surname>Pibarot</surname> <given-names>P</given-names>
</name>
<name>
<surname>Biertho</surname> <given-names>L</given-names>
</name>
<name>
<surname>Tchernof</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>Association between circulating amino acids and COVID-19 severity</article-title>. <source>Metabolites</source>. (<year>2023</year>) <volume>13</volume>(<issue>2</issue>):<fpage>201</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/metabo13020201</pub-id>
</citation>
</ref>
<ref id="B39">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mason</surname> <given-names>S</given-names>
</name>
<name>
<surname>van Reenen</surname> <given-names>M</given-names>
</name>
<name>
<surname>Rossouw</surname> <given-names>T</given-names>
</name>
<name>
<surname>Lindeque</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Louw</surname> <given-names>R</given-names>
</name>
</person-group>. <article-title>Phenylalanine metabolism and tetrahydrobiopterin bio-availability in COVID-19 and HIV</article-title>. <source>Heliyon</source>. (<year>2023</year>) <volume>9</volume>:<elocation-id>e15010</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.heliyon.2023.e15010</pub-id>
</citation>
</ref>
<ref id="B40">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xue</surname> <given-names>C</given-names>
</name>
<name>
<surname>Li</surname> <given-names>G</given-names>
</name>
<name>
<surname>Zheng</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Gu</surname> <given-names>X</given-names>
</name>
<name>
<surname>Shi</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Su</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Tryptophan metabolism in health and disease</article-title>. <source>Cell Metab</source>. (<year>2023</year>) <volume>35</volume>(<issue>8</issue>):<page-range>1304&#x2013;26</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.cmet.2023.06.004</pub-id>
</citation>
</ref>
<ref id="B41">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Masoodi</surname> <given-names>M</given-names>
</name>
<name>
<surname>Peschka</surname> <given-names>M</given-names>
</name>
<name>
<surname>Schmiedel</surname> <given-names>S</given-names>
</name>
<name>
<surname>Haddad</surname> <given-names>M</given-names>
</name>
<name>
<surname>Frye</surname> <given-names>M</given-names>
</name>
<name>
<surname>Maas</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Disturbed lipid and amino acid metabolisms in COVID-19 patients</article-title>. <source>J Mol Med (Berl)</source>. (<year>2022</year>) <volume>100</volume>:<page-range>555&#x2013;68</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00109-022-02177-4</pub-id>
</citation>
</ref>
<ref id="B42">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Munn</surname> <given-names>DH</given-names>
</name>
<name>
<surname>Mellor</surname> <given-names>AL</given-names>
</name>
</person-group>. <article-title>Indoleamine 2,3 dioxygenase and metabolic control of immune responses</article-title>. <source>Trends Immunol</source>. (<year>2013</year>) <volume>34</volume>:<page-range>137&#x2013;43</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.it.2012.10.001</pub-id>
</citation>
</ref>
<ref id="B43">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McCann</surname> <given-names>MR</given-names>
</name>
<name>
<surname>George de la Rosa</surname> <given-names>MV</given-names>
</name>
<name>
<surname>Rosania</surname> <given-names>GR</given-names>
</name>
<name>
<surname>Stringer</surname> <given-names>KA</given-names>
</name>
</person-group>. <article-title>L-carnitine and acylcarnitines: mitochondrial biomarkers for precision medicine</article-title>. <source>Metabolites</source>. (<year>2021</year>) <volume>11</volume>(<issue>1</issue>):<fpage>51</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/metabo11010051</pub-id>
</citation>
</ref>
<ref id="B44">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sozio</surname> <given-names>E</given-names>
</name>
<name>
<surname>Hannemann</surname> <given-names>J</given-names>
</name>
<name>
<surname>Fabris</surname> <given-names>M</given-names>
</name>
<name>
<surname>Cifu</surname> <given-names>A</given-names>
</name>
<name>
<surname>Ripoli</surname> <given-names>A</given-names>
</name>
<name>
<surname>Sbrana</surname> <given-names>F</given-names>
</name>
<etal/>
</person-group>. <article-title>The role of asymmetric dimethylarginine (ADMA) in COVID-19: association with respiratory failure and predictive role for outcome</article-title>. <source>Sci Rep</source>. (<year>2023</year>) <volume>13</volume>:<fpage>9811</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41598-023-36954-z</pub-id>
</citation>
</ref>
<ref id="B45">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Andrew</surname> <given-names>PJ</given-names>
</name>
<name>
<surname>Mayer</surname> <given-names>B</given-names>
</name>
</person-group>. <article-title>Enzymatic function of nitric oxide synthases</article-title>. <source>Cardiovasc Res</source>. (<year>1999</year>) <volume>43</volume>:<page-range>521&#x2013;31</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/s0008-6363(99)00115-7</pub-id>
</citation>
</ref>
<ref id="B46">
<label>46</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gambardella</surname> <given-names>J</given-names>
</name>
<name>
<surname>Khondkar</surname> <given-names>W</given-names>
</name>
<name>
<surname>Morelli</surname> <given-names>MB</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Santulli</surname> <given-names>G</given-names>
</name>
<name>
<surname>Trimarco</surname> <given-names>V</given-names>
</name>
</person-group>. <article-title>Arginine and endothelial function</article-title>. <source>Biomedicines</source>. (<year>2020</year>) <volume>8</volume>(<issue>8</issue>):<fpage>277</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/biomedicines8080277</pub-id>
</citation>
</ref>
<ref id="B47">
<label>47</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hsu</surname> <given-names>CN</given-names>
</name>
<name>
<surname>Tain</surname> <given-names>YL</given-names>
</name>
</person-group>. <article-title>Impact of arginine nutrition and metabolism during pregnancy on offspring outcomes</article-title>. <source>Nutrients</source>. (<year>2019</year>) <volume>11</volume>(<issue>7</issue>):<fpage>1452</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/nu11071452</pub-id>
</citation>
</ref>
<ref id="B48">
<label>48</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boger</surname> <given-names>RH</given-names>
</name>
</person-group>. <article-title>The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor</article-title>. <source>Cardiovasc Res</source>. (<year>2003</year>) <volume>59</volume>:<page-range>824&#x2013;33</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/s0008-6363(03)00500-5</pub-id>
</citation>
</ref>
<ref id="B49">
<label>49</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hannemann</surname> <given-names>J</given-names>
</name>
<name>
<surname>Zummack</surname> <given-names>J</given-names>
</name>
<name>
<surname>Hillig</surname> <given-names>J</given-names>
</name>
<name>
<surname>Boger</surname> <given-names>R</given-names>
</name>
</person-group>. <article-title>Metabolism of asymmetric dimethylarginine in hypoxia: from bench to bedside</article-title>. <source>Pulm Circ</source>. (<year>2020</year>) <volume>10</volume>:<elocation-id>2045894020918846</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1177/2045894020918846</pub-id>
</citation>
</ref>
<ref id="B50">
<label>50</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boger</surname> <given-names>RH</given-names>
</name>
</person-group>. <article-title>Live and let die: asymmetric dimethylarginine and septic shock</article-title>. <source>Crit Care</source>. (<year>2006</year>) <volume>10</volume>:<fpage>169</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/cc5076</pub-id>
</citation>
</ref>
<ref id="B51">
<label>51</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hannemann</surname> <given-names>J</given-names>
</name>
<name>
<surname>Balfanz</surname> <given-names>P</given-names>
</name>
<name>
<surname>Schwedhelm</surname> <given-names>E</given-names>
</name>
<name>
<surname>Hartmann</surname> <given-names>B</given-names>
</name>
<name>
<surname>Ule</surname> <given-names>J</given-names>
</name>
<name>
<surname>Muller-Wieland</surname> <given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Elevated serum SDMA and ADMA at hospital admission predict in-hospital mortality of COVID-19 patients</article-title>. <source>Sci Rep</source>. (<year>2021</year>) <volume>11</volume>:<fpage>9895</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41598-021-89180-w</pub-id>
</citation>
</ref>
<ref id="B52">
<label>52</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van Calster</surname> <given-names>B</given-names>
</name>
<name>
<surname>Wynants</surname> <given-names>L</given-names>
</name>
</person-group>. <article-title>Machine learning in medicine</article-title>. <source>N Engl J Med</source>. (<year>2019</year>) <volume>380</volume>:<fpage>2588</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1056/NEJMc1906060</pub-id>
</citation>
</ref>
<ref id="B53">
<label>53</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lambin</surname> <given-names>P</given-names>
</name>
<name>
<surname>Leijenaar</surname> <given-names>RTH</given-names>
</name>
<name>
<surname>Deist</surname> <given-names>TM</given-names>
</name>
<name>
<surname>Peerlings</surname> <given-names>J</given-names>
</name>
<name>
<surname>de Jong</surname> <given-names>EEC</given-names>
</name>
<name>
<surname>van Timmeren</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Radiomics: the bridge between medical imaging and personalized medicine</article-title>. <source>Nat Rev Clin Oncol</source>. (<year>2017</year>) <volume>14</volume>:<page-range>749&#x2013;62</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nrclinonc.2017.141</pub-id>
</citation>
</ref>
<ref id="B54">
<label>54</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yue</surname> <given-names>H</given-names>
</name>
<name>
<surname>Yu</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>C</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Jiang</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Shao</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Machine learning-based CT radiomics method for predicting hospital stay in patients with pneumonia associated with SARS-CoV-2 infection: a multicenter study</article-title>. <source>Ann Transl Med</source>. (<year>2020</year>) <volume>8</volume>:<fpage>859</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.21037/atm-20-3026</pub-id>
</citation>
</ref>
<ref id="B55">
<label>55</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alakus</surname> <given-names>TB</given-names>
</name>
<name>
<surname>Turkoglu</surname> <given-names>I</given-names>
</name>
</person-group>. <article-title>Comparison of deep learning approaches to predict COVID-19 infection</article-title>. <source>Chaos Solitons Fractals</source>. (<year>2020</year>) <volume>140</volume>:<elocation-id>110120</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.chaos.2020.110120</pub-id>
</citation>
</ref>
<ref id="B56">
<label>56</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cohen</surname> <given-names>JP</given-names>
</name>
<name>
<surname>Dao</surname> <given-names>L</given-names>
</name>
<name>
<surname>Roth</surname> <given-names>K</given-names>
</name>
<name>
<surname>Morrison</surname> <given-names>P</given-names>
</name>
<name>
<surname>Bengio</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Abbasi</surname> <given-names>AF</given-names>
</name>
<etal/>
</person-group>. <article-title>Predicting COVID-19 pneumonia severity on chest X-ray with deep learning</article-title>. <source>Cureus</source>. (<year>2020</year>) <volume>12</volume>:<elocation-id>9448</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.7759/cureus.9448</pub-id>
</citation>
</ref>
<ref id="B57">
<label>57</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liang</surname> <given-names>W</given-names>
</name>
<name>
<surname>Yao</surname> <given-names>J</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>A</given-names>
</name>
<name>
<surname>Lv</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Zanin</surname> <given-names>M</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Early triage of critically ill COVID-19 patients using deep learning</article-title>. <source>Nat Commun</source>. (<year>2020</year>) <volume>11</volume>:<fpage>3543</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41467-020-17280-8</pub-id>
</citation>
</ref>
<ref id="B58">
<label>58</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fernandez</surname> <given-names>A</given-names>
</name>
<name>
<surname>ObieChina</surname> <given-names>N</given-names>
</name>
<name>
<surname>Koh</surname> <given-names>J</given-names>
</name>
<name>
<surname>Hong</surname> <given-names>A</given-names>
</name>
<name>
<surname>Nandi</surname> <given-names>A</given-names>
</name>
<name>
<surname>Reynolds</surname> <given-names>TM</given-names>
</name>
</person-group>. <article-title>Survival prediction algorithms for COVID-19 patients admitted to a UK district general hospital</article-title>. <source>Int J Clin Pract</source>. (<year>2021</year>) <volume>75</volume>:<fpage>e13974</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/ijcp.13974</pub-id>
</citation>
</ref>
<ref id="B59">
<label>59</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Taheriyan</surname> <given-names>M</given-names>
</name>
<name>
<surname>Ayyoubzadeh</surname> <given-names>SM</given-names>
</name>
<name>
<surname>Ebrahimi</surname> <given-names>M</given-names>
</name>
<name>
<surname>Niakan Kalhori</surname> <given-names>SR</given-names>
</name>
<name>
<surname>Abooei</surname> <given-names>AH</given-names>
</name>
<name>
<surname>Gholamzadeh</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Prediction of COVID-19 patients&#x2019; Survival by deep learning approaches</article-title>. <source>Med J Islam Repub Iran</source>. (<year>2022</year>) <volume>36</volume>:<elocation-id>144</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.47176/mjiri.36.144</pub-id>
</citation>
</ref>
<ref id="B60">
<label>60</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ayres</surname> <given-names>JS</given-names>
</name>
</person-group>. <article-title>A metabolic handbook for the COVID-19 pandemic</article-title>. <source>Nat Metab</source>. (<year>2020</year>) <volume>2</volume>:<page-range>572&#x2013;85</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s42255-020-0237-2</pub-id>
</citation>
</ref>
<ref id="B61">
<label>61</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shen</surname> <given-names>B</given-names>
</name>
<name>
<surname>Yi</surname> <given-names>X</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Bi</surname> <given-names>X</given-names>
</name>
<name>
<surname>Du</surname> <given-names>J</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Proteomic and metabolomic characterization of COVID-19 patient sera</article-title>. <source>Cell</source>. (<year>2020</year>) <volume>182</volume>:<fpage>59</fpage>&#x2013;<lpage>72 e15</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.cell.2020.05.032</pub-id>
</citation>
</ref>
<ref id="B62">
<label>62</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Atila</surname> <given-names>A</given-names>
</name>
<name>
<surname>Alay</surname> <given-names>H</given-names>
</name>
<name>
<surname>Yaman</surname> <given-names>ME</given-names>
</name>
<name>
<surname>Akman</surname> <given-names>TC</given-names>
</name>
<name>
<surname>Cadirci</surname> <given-names>E</given-names>
</name>
<name>
<surname>Bayrak</surname> <given-names>B</given-names>
</name>
<etal/>
</person-group>. <article-title>The serum amino acid profile in COVID-19</article-title>. <source>Amino Acids</source>. (<year>2021</year>) <volume>53</volume>:<page-range>1569&#x2013;88</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00726-021-03081-w</pub-id>
</citation>
</ref>
<ref id="B63">
<label>63</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname> <given-names>G</given-names>
</name>
</person-group>. <article-title>Amino acids: metabolism, functions, and nutrition</article-title>. <source>Amino Acids</source>. (<year>2009</year>) <volume>37</volume>:<fpage>1</fpage>&#x2013;<lpage>17</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00726-009-0269-0</pub-id>
</citation>
</ref>
<ref id="B64">
<label>64</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Petersen</surname> <given-names>KF</given-names>
</name>
<name>
<surname>Dufour</surname> <given-names>S</given-names>
</name>
<name>
<surname>Cline</surname> <given-names>GW</given-names>
</name>
<name>
<surname>Shulman</surname> <given-names>GI</given-names>
</name>
</person-group>. <article-title>Regulation of hepatic mitochondrial oxidation by glucose-alanine cycling during starvation in humans</article-title>. <source>J Clin Invest</source>. (<year>2019</year>) <volume>129</volume>:<page-range>4671&#x2013;5</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1172/JCI129913</pub-id>
</citation>
</ref>
<ref id="B65">
<label>65</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Waskiw-Ford</surname> <given-names>M</given-names>
</name>
<name>
<surname>Hannaian</surname> <given-names>S</given-names>
</name>
<name>
<surname>Duncan</surname> <given-names>J</given-names>
</name>
<name>
<surname>Kato</surname> <given-names>H</given-names>
</name>
<name>
<surname>Abou Sawan</surname> <given-names>S</given-names>
</name>
<name>
<surname>Locke</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Leucine-enriched essential amino acids improve recovery from post-exercise muscle damage independent of increases in integrated myofibrillar protein synthesis in young men</article-title>. <source>Nutrients</source>. (<year>2020</year>) <volume>12</volume>(<issue>4</issue>):<fpage>1061</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/nu12041061</pub-id>
</citation>
</ref>
<ref id="B66">
<label>66</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paez-Franco</surname> <given-names>JC</given-names>
</name>
<name>
<surname>Torres-Ruiz</surname> <given-names>J</given-names>
</name>
<name>
<surname>Sosa-Hernandez</surname> <given-names>VA</given-names>
</name>
<name>
<surname>Cervantes-Diaz</surname> <given-names>R</given-names>
</name>
<name>
<surname>Romero-Ramirez</surname> <given-names>S</given-names>
</name>
<name>
<surname>Perez-Fragoso</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Metabolomics analysis reveals a modified amino acid metabolism that correlates with altered oxygen homeostasis in COVID-19 patients</article-title>. <source>Sci Rep</source>. (<year>2021</year>) <volume>11</volume>:<fpage>6350</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41598-021-85788-0</pub-id>
</citation>
</ref>
<ref id="B67">
<label>67</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Philips</surname> <given-names>AM</given-names>
</name>
<name>
<surname>Khan</surname> <given-names>N</given-names>
</name>
</person-group>. <article-title>Amino acid sensing pathway: A major check point in the pathogenesis of obesity and COVID-19</article-title>. <source>Obes Rev</source>. (<year>2021</year>) <volume>22</volume>:<elocation-id>e13221</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/obr.13221</pub-id>
</citation>
</ref>
<ref id="B68">
<label>68</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cai</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>DJ</given-names>
</name>
<name>
<surname>Takahashi</surname> <given-names>T</given-names>
</name>
<name>
<surname>Broadhurst</surname> <given-names>DI</given-names>
</name>
<name>
<surname>Yan</surname> <given-names>H</given-names>
</name>
<name>
<surname>Ma</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Kynurenic acid may underlie sex-specific immune responses to COVID-19</article-title>. <source>Sci Signal</source>. (<year>2021</year>) <volume>14</volume>(<issue>690</issue>):<elocation-id>eabf8483</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1126/scisignal.abf8483</pub-id>
</citation>
</ref>
<ref id="B69">
<label>69</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Federica</surname> <given-names>G</given-names>
</name>
<name>
<surname>Giuseppina</surname> <given-names>F</given-names>
</name>
<name>
<surname>Veronica</surname> <given-names>L</given-names>
</name>
<name>
<surname>Gianpaolo</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Massimo</surname> <given-names>T</given-names>
</name>
<name>
<surname>Veronica</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>An untargeted metabolomic approach to investigate antiviral defence mechanisms in memory leukocytes secreting anti-SARS-CoV-2 IgG <italic>in vitro</italic>
</article-title>. <source>Sci Rep</source>. (<year>2023</year>) <volume>13</volume>:<fpage>629</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41598-022-26156-4</pub-id>
</citation>
</ref>
<ref id="B70">
<label>70</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mondanelli</surname> <given-names>G</given-names>
</name>
<name>
<surname>Bianchi</surname> <given-names>R</given-names>
</name>
<name>
<surname>Pallotta</surname> <given-names>MT</given-names>
</name>
<name>
<surname>Orabona</surname> <given-names>C</given-names>
</name>
<name>
<surname>Albini</surname> <given-names>E</given-names>
</name>
<name>
<surname>Iacono</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>A relay pathway between arginine and tryptophan metabolism confers immunosuppressive properties on dendritic cells</article-title>. <source>Immunity</source>. (<year>2017</year>) <volume>46</volume>:<page-range>233&#x2013;44</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.immuni.2017.01.005</pub-id>
</citation>
</ref>
<ref id="B71">
<label>71</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dewulf</surname> <given-names>JP</given-names>
</name>
<name>
<surname>Martin</surname> <given-names>M</given-names>
</name>
<name>
<surname>Marie</surname> <given-names>S</given-names>
</name>
<name>
<surname>Oguz</surname> <given-names>F</given-names>
</name>
<name>
<surname>Belkhir</surname> <given-names>L</given-names>
</name>
<name>
<surname>De Greef</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Urine metabolomics links dysregulation of the tryptophan-kynurenine pathway to inflammation and severity of COVID-19</article-title>. <source>Sci Rep</source>. (<year>2022</year>) <volume>12</volume>:<elocation-id>9959</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41598-022-14292-w</pub-id>
</citation>
</ref>
<ref id="B72">
<label>72</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Valdes</surname> <given-names>A</given-names>
</name>
<name>
<surname>Moreno</surname> <given-names>LO</given-names>
</name>
<name>
<surname>Rello</surname> <given-names>SR</given-names>
</name>
<name>
<surname>Orduna</surname> <given-names>A</given-names>
</name>
<name>
<surname>Bernardo</surname> <given-names>D</given-names>
</name>
<name>
<surname>Cifuentes</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>Metabolomics study of COVID-19 patients in four different clinical stages</article-title>. <source>Sci Rep</source>. (<year>2022</year>) <volume>12</volume>:<fpage>1650</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41598-022-05667-0</pub-id>
</citation>
</ref>
<ref id="B73">
<label>73</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hanai</surname> <given-names>T</given-names>
</name>
<name>
<surname>Shiraki</surname> <given-names>M</given-names>
</name>
<name>
<surname>Imai</surname> <given-names>K</given-names>
</name>
<name>
<surname>Suetugu</surname> <given-names>A</given-names>
</name>
<name>
<surname>Takai</surname> <given-names>K</given-names>
</name>
<name>
<surname>Shimizu</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>Usefulness of carnitine supplementation for the complications of liver cirrhosis</article-title>. <source>Nutrients</source>. (<year>2020</year>) <volume>12</volume>(<issue>7</issue>):<fpage>1</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/nu12071915</pub-id>
</citation>
</ref>
<ref id="B74">
<label>74</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vaz</surname> <given-names>FM</given-names>
</name>
<name>
<surname>Wanders</surname> <given-names>RJ</given-names>
</name>
</person-group>. <article-title>Carnitine biosynthesis in mammals</article-title>. <source>Biochem J</source>. (<year>2002</year>) <volume>361</volume>:<page-range>417&#x2013;29</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1042/0264-6021:3610417</pub-id>
</citation>
</ref>
<ref id="B75">
<label>75</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Herrera-Van Oostdam</surname> <given-names>AS</given-names>
</name>
<name>
<surname>Castaneda-Delgado</surname> <given-names>JE</given-names>
</name>
<name>
<surname>Oropeza-Valdez</surname> <given-names>JJ</given-names>
</name>
<name>
<surname>Borrego</surname> <given-names>JC</given-names>
</name>
<name>
<surname>Monarrez-Espino</surname> <given-names>J</given-names>
</name>
<name>
<surname>Zheng</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Immunometabolic signatures predict risk of progression to sepsis in COVID-19</article-title>. <source>PloS One</source>. (<year>2021</year>) <volume>16</volume>:<elocation-id>e0256784</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.pone.0256784</pub-id>
</citation>
</ref>
<ref id="B76">
<label>76</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thomas</surname> <given-names>T</given-names>
</name>
<name>
<surname>Stefanoni</surname> <given-names>D</given-names>
</name>
<name>
<surname>Dzieciatkowska</surname> <given-names>M</given-names>
</name>
<name>
<surname>Issaian</surname> <given-names>A</given-names>
</name>
<name>
<surname>Nemkov</surname> <given-names>T</given-names>
</name>
<name>
<surname>Hill</surname> <given-names>RC</given-names>
</name>
<etal/>
</person-group>. <article-title>Evidence of structural protein damage and membrane lipid remodeling in red blood cells from COVID-19 patients</article-title>. <source>J Proteome Res</source>. (<year>2020</year>) <volume>19</volume>:<page-range>4455&#x2013;69</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1021/acs.jproteome.0c00606</pub-id>
</citation>
</ref>
<ref id="B77">
<label>77</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname> <given-names>K</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Dai</surname> <given-names>D</given-names>
</name>
<name>
<surname>Feng</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>L</given-names>
</name>
<name>
<surname>Nie</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>Serum iron level as a potential predictor of coronavirus disease 2019 severity and mortality: A retrospective study</article-title>. <source>Open Forum Infect Dis</source>. (<year>2020</year>) <volume>7</volume>:<elocation-id>ofaa250</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/ofid/ofaa250</pub-id>
</citation>
</ref>
<ref id="B78">
<label>78</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Henry</surname> <given-names>BM</given-names>
</name>
<name>
<surname>de Oliveira</surname> <given-names>MHS</given-names>
</name>
<name>
<surname>Benoit</surname> <given-names>S</given-names>
</name>
<name>
<surname>Plebani</surname> <given-names>M</given-names>
</name>
<name>
<surname>Lippi</surname> <given-names>G</given-names>
</name>
</person-group>. <article-title>Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis</article-title>. <source>Clin Chem Lab Med</source>. (<year>2020</year>) <volume>58</volume>:<page-range>1021&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1515/cclm-2020-0369</pub-id>
</citation>
</ref>
<ref id="B79">
<label>79</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Phua</surname> <given-names>J</given-names>
</name>
<name>
<surname>Weng</surname> <given-names>L</given-names>
</name>
<name>
<surname>Ling</surname> <given-names>L</given-names>
</name>
<name>
<surname>Egi</surname> <given-names>M</given-names>
</name>
<name>
<surname>Lim</surname> <given-names>CM</given-names>
</name>
<name>
<surname>Divatia</surname> <given-names>JV</given-names>
</name>
<etal/>
</person-group>. <article-title>Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations</article-title>. <source>Lancet Respir Med</source>. (<year>2020</year>) <volume>8</volume>:<page-range>506&#x2013;17</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/S2213-2600(20)30161-2</pub-id>
</citation>
</ref>
<ref id="B80">
<label>80</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname> <given-names>F</given-names>
</name>
<name>
<surname>Yu</surname> <given-names>T</given-names>
</name>
<name>
<surname>Du</surname> <given-names>R</given-names>
</name>
<name>
<surname>Fan</surname> <given-names>G</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>Z</given-names>
</name>
<etal/>
</person-group>. <article-title>Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study</article-title>. <source>Lancet</source>. (<year>2020</year>) <volume>395</volume>:<page-range>1054&#x2013;62</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/S0140-6736(20)30566-3</pub-id>
</citation>
</ref>
<ref id="B81">
<label>81</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname> <given-names>C</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>X</given-names>
</name>
<name>
<surname>Cai</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Xia</surname> <given-names>J</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>X</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in wuhan, China</article-title>. <source>JAMA Intern Med</source>. (<year>2020</year>) <volume>180</volume>:<page-range>934&#x2013;43</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1001/jamainternmed.2020.0994</pub-id>
</citation>
</ref>
<ref id="B82">
<label>82</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kernan</surname> <given-names>KF</given-names>
</name>
<name>
<surname>Carcillo</surname> <given-names>JA</given-names>
</name>
</person-group>. <article-title>Hyperferritinemia and inflammation</article-title>. <source>Int Immunol</source>. (<year>2017</year>) <volume>29</volume>:<page-range>401&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/intimm/dxx031</pub-id>
</citation>
</ref>
<ref id="B83">
<label>83</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hadi</surname> <given-names>JM</given-names>
</name>
<name>
<surname>Mohammad</surname> <given-names>HM</given-names>
</name>
<name>
<surname>Ahmed</surname> <given-names>AY</given-names>
</name>
<name>
<surname>Tofiq</surname> <given-names>SS</given-names>
</name>
<name>
<surname>Abdalrahman</surname> <given-names>LB</given-names>
</name>
<name>
<surname>Qasm</surname> <given-names>AA</given-names>
</name>
<etal/>
</person-group>. <article-title>Investigation of serum ferritin for the prediction of COVID-19 severity and mortality: A cross-sectional study</article-title>. <source>Cureus</source>. (<year>2022</year>) <volume>14</volume>:<elocation-id>e31982</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.7759/cureus.31982</pub-id>
</citation>
</ref>
<ref id="B84">
<label>84</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kaushal</surname> <given-names>K</given-names>
</name>
<name>
<surname>Kaur</surname> <given-names>H</given-names>
</name>
<name>
<surname>Sarma</surname> <given-names>P</given-names>
</name>
<name>
<surname>Bhattacharyya</surname> <given-names>A</given-names>
</name>
<name>
<surname>Sharma</surname> <given-names>DJ</given-names>
</name>
<name>
<surname>Prajapat</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Serum ferritin as a predictive biomarker in COVID-19. A systematic review, meta-analysis and meta-regression analysis</article-title>. <source>J Crit Care</source>. (<year>2022</year>) <volume>67</volume>:<page-range>172&#x2013;81</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jcrc.2021.09.023</pub-id>
</citation>
</ref>
<ref id="B85">
<label>85</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Habib</surname> <given-names>HM</given-names>
</name>
<name>
<surname>Ibrahim</surname> <given-names>S</given-names>
</name>
<name>
<surname>Zaim</surname> <given-names>A</given-names>
</name>
<name>
<surname>Ibrahim</surname> <given-names>WH</given-names>
</name>
</person-group>. <article-title>The role of iron in the pathogenesis of COVID-19 and possible treatment with lactoferrin and other iron chelators</article-title>. <source>BioMed Pharmacother</source>. (<year>2021</year>) <volume>136</volume>:<elocation-id>111228</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.biopha.2021.111228</pub-id>
</citation>
</ref>
<ref id="B86">
<label>86</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vargas-Vargas</surname> <given-names>M</given-names>
</name>
<name>
<surname>Cortes-Rojo</surname> <given-names>C</given-names>
</name>
</person-group>. <article-title>Ferritin levels and COVID-19</article-title>. <source>Rev Panam Salud Publica</source>. (<year>2020</year>) <volume>44</volume>:<elocation-id>e72</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.26633/RPSP.2020.72</pub-id>
</citation>
</ref>
<ref id="B87">
<label>87</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fratta Pasini</surname> <given-names>AM</given-names>
</name>
<name>
<surname>Stranieri</surname> <given-names>C</given-names>
</name>
<name>
<surname>Girelli</surname> <given-names>D</given-names>
</name>
<name>
<surname>Busti</surname> <given-names>F</given-names>
</name>
<name>
<surname>Cominacini</surname> <given-names>L</given-names>
</name>
</person-group>. <article-title>Is ferroptosis a key component of the process leading to multiorgan damage in COVID-19</article-title>? <source>Antioxid (Basel)</source>. (<year>2021</year>) <volume>10</volume>(<issue>11</issue>):<fpage>1677</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/antiox10111677</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>